<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">68563</article-id><article-id pub-id-type="doi">10.7554/eLife.68563</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-129082"><name><surname>Khan</surname><given-names>Shahanshah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3052-932X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-258676"><name><surname>Shafiei</surname><given-names>Mahnoush S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-232872"><name><surname>Longoria</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-62461"><name><surname>Schoggins</surname><given-names>John W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7944-6800</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-158295"><name><surname>Savani</surname><given-names>Rashmin C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-117769"><name><surname>Zaki</surname><given-names>Hasan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9002-5399</contrib-id><email>hasan.zaki@utsouthwestern.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Pathology, The University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Pediatrics, The University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Department of Microbiology, The University of Texas Southwestern Medical Center</institution><addr-line><named-content content-type="city">Dallas</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution>Institute of Industrial Science, The University of Tokyo</institution><country>Japan</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>06</day><month>12</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e68563</elocation-id><history><date date-type="received" iso-8601-date="2021-03-19"><day>19</day><month>03</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-12-01"><day>01</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Khan et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Khan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-68563-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-68563-figures-v3.pdf"/><related-article ext-link-type="doi" id="ra1" related-article-type="commentary" xlink:href="10.7554/eLife.76231"/><abstract><p>The pathogenesis of COVID-19 is associated with a hyperinflammatory response; however, the precise mechanism of SARS-CoV-2-induced inflammation is poorly understood. Here, we investigated direct inflammatory functions of major structural proteins of SARS-CoV-2. We observed that spike (S) protein potently induced inflammatory cytokines and chemokines, including IL-6, IL-1β, TNFα, CXCL1, CXCL2, and CCL2, but not IFNs in human and mouse macrophages. No such inflammatory response was observed in response to membrane (M), envelope (E), and nucleocapsid (N) proteins. When stimulated with extracellular S protein, human and mouse lung epithelial cells also produced inflammatory cytokines and chemokines. Interestingly, epithelial cells expressing S protein intracellularly were non-inflammatory, but elicited an inflammatory response in macrophages when co-cultured. Biochemical studies revealed that S protein triggers inflammation via activation of the NF-κB pathway in a MyD88-dependent manner. Further, such an activation of the NF-κB pathway was abrogated in Tlr2-deficient macrophages. Consistently, administration of S protein-induced IL-6, TNF-α, and IL-1β in wild-type, but not Tlr2-deficient mice. Notably, upon recognition of S protein, TLR2 dimerizes with TLR1 or TLR6 to activate the NF-κB pathway. Taken together, these data reveal a mechanism for the cytokine storm during SARS-CoV-2 infection and suggest that TLR2 could be a potential therapeutic target for COVID-19.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>spike protein</kwd><kwd>cytokine storm</kwd><kwd>TLR2</kwd><kwd>inflammation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RP200284</award-id><principal-award-recipient><name><surname>Zaki</surname><given-names>Hasan</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK125352</award-id><principal-award-recipient><name><surname>Zaki</surname><given-names>Hasan</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI158124</award-id><principal-award-recipient><name><surname>Schoggins</surname><given-names>John W</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>Research Scholar RSG-21-021-01-TBE</award-id><principal-award-recipient><name><surname>Zaki</surname><given-names>Hasan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Recognition of SARS-CoV-2 spike protein by innate immune sensor TLR2 leads to the induction of inflammatory mediators and constitutes a mechanism for cytokine storm during COVID-19.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Coronavirus induced disease (COVID)19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a major public health crisis since December 2019 (<xref ref-type="bibr" rid="bib54">Zhou et al., 2020b</xref>; <xref ref-type="bibr" rid="bib47">Wu et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Huang et al., 2020</xref>). SARS-CoV-2 is a positive sense single-stranded RNA virus. Like other coronaviruses, such as SARS (retrospectively named SARS-CoV-1) and Middle Eastern respiratory syndrome (MERS)-CoV, SARS-CoV-2 primarily causes infection in the respiratory tract, leading to either asymptomatic infection or a range of symptoms including cough, fever, pneumonia, respiratory failure, along with other complications like diarrhea and multi-organ failure (<xref ref-type="bibr" rid="bib42">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Tay et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Li et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Gu et al., 2005</xref>). In the absence of effective therapies, COVID-19 has caused over 4 million deaths worldwide by the end of 2021. Although our knowledge is still evolving, immunopathology caused by the cytokine storm plays a decisive role in COVID-19 pathogenesis (<xref ref-type="bibr" rid="bib42">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Tay et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Blanco-Melo et al., 2020</xref>).</p><p>SARS-CoV-2 infects human cells through its Spike (S) protein, which binds to the receptor angiotensin-converting enzyme 2 (ACE2), expressed on alveolar epithelial cells, allowing endocytosis of the viral particle (<xref ref-type="bibr" rid="bib54">Zhou et al., 2020b</xref>; <xref ref-type="bibr" rid="bib17">Hoffmann et al., 2020</xref>). Following endocytosis, the viral genome is replicated using both viral and host machineries, leading to the death of virally infected cells (<xref ref-type="bibr" rid="bib44">Walls et al., 2020</xref>). The pathology of SARS-CoV-2 infected lung is further worsened with inflammatory responses of innate immune cells such as macrophages, monocytes, and neutrophils, which are activated by viral components and products of apoptotic and necrotic cells (<xref ref-type="bibr" rid="bib19">Huang et al., 2020</xref>). While the innate immune response is essential for antiviral host defense, excessive inflammatory cytokines and chemokines are cytotoxic for respiratory epithelial cells and vascular endothelial cells (<xref ref-type="bibr" rid="bib50">Xu et al., 2020</xref>). Indeed, the clinical manifestation of COVID-19 is marked by higher concentrations of IL-2, IL-6, IL-8, TNFα, IFNγ, MCP1, MIP1α, IP-10, and GMCSF in patients’ blood (<xref ref-type="bibr" rid="bib19">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Mehta et al., 2020</xref>). Disease severity and death of COVID-19 patients have been correlated to the elevated expression of IL-6 and TNFα (<xref ref-type="bibr" rid="bib19">Huang et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Hadjadj et al., 2020</xref>). However, our understanding of the precise mechanism of the induction of proinflammatory cytokines and chemokines during SARS-CoV-2 infection is very limited.</p><p>The innate immune inflammatory response is initiated with the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I like receptors (RLRs). Activated PRRs involve multiple signaling adapters to activate transcription factors, such as NF-κB, AP1, and IRF3, which regulate the expression of genes involved in immunity and inflammation. RNA sensing receptors such as TLR7, RIG-I, and MDA5 play a central role in antiviral immunity by inducing type I interferons (IFNα and IFNβ) via IRF3 and NF-κB (<xref ref-type="bibr" rid="bib25">Khan et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Park and Iwasaki, 2020</xref>; <xref ref-type="bibr" rid="bib24">Kawasaki and Kawai, 2014</xref>; <xref ref-type="bibr" rid="bib23">Kawai and Akira, 2006</xref>; <xref ref-type="bibr" rid="bib20">Jensen and Thomsen, 2012</xref>). Although the relative contribution of RNA sensing pathways in SARS-CoV-2-mediated immunopathology is yet to be explored, previous studies reported that macrophages and dendritic cells infected with SARS-CoV-1 produce proinflammatory cytokines and chemokines, but not type I interferons (<xref ref-type="bibr" rid="bib6">Cheung et al., 2005</xref>; <xref ref-type="bibr" rid="bib27">Law et al., 2005</xref>). Consistently, inflammatory responses in severe COVID-19 patients are characterized by high levels of proinflammatory cytokines, but poor type I interferon response (<xref ref-type="bibr" rid="bib2">Blanco-Melo et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Hadjadj et al., 2020</xref>). Beyond these phenotypic observations, the precise mechanism of the hyperinflammatory response during SARS-CoV-2 infection is poorly understood.</p><p>SARS-CoV-2 is an enveloped virus consisting of four major structural proteins—S, nucleocapsid (N), membrane (M), and envelop (E) (<xref ref-type="bibr" rid="bib7">de Wit et al., 2016</xref>). S protein binds to the receptor-binding domain of ACE2 through its S1 subunit allowing proteasomal cleavage of S protein and fusion of the S2 subunit with the host cell membrane (<xref ref-type="bibr" rid="bib17">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Walls et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Li et al., 2003</xref>; <xref ref-type="bibr" rid="bib1">Bertram et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Shirato et al., 2011</xref>). Thus, SARS-CoV-2 structural proteins are likely to be exposed to PRRs located on the cell membrane, endosome, and cytosol of the infected cell. However, our knowledge of the role of SARS-CoV-2 structural proteins in the innate immune response is very limited. Here, we investigated the inflammatory properties of S, M, N, and E proteins and revealed that S protein, but not M, N, and E proteins, is a potent viral PAMP, which stimulates macrophages, monocytes, and lung epithelial cells. We demonstrated that S protein is sensed by TLR2, leading to the activation of the NF-κB pathway and induction of inflammatory cytokines and chemokines. This study provides critical insight into the molecular mechanism that may contribute to cytokine storm during SARS-CoV-2 infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SARS-CoV-2 S protein induces inflammatory cytokines and chemokines in macrophages and monocytes</title><p>Macrophages play a central role in the hyperinflammatory response during SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib13">Grant et al., 2021</xref>). To understand whether SARS-CoV-2 structural proteins can activate macrophages and monocytes, we stimulated human monocytic cell THP1-derived macrophages with recombinant S1, S2, M, N, and E proteins. Interestingly, both S1 and S2 proteins induced proinflammatory cytokines <italic>IL6</italic>, <italic>TNFA</italic>, and <italic>IL1B</italic>, with S2 being more potent, as measured by real-time RT-PCR and ELISA (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Chemokines produced by macrophages and monocytes recruit T lymphocytes and other immune cells in the inflamed tissue, aggravating inflammatory damage (<xref ref-type="bibr" rid="bib42">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Grant et al., 2021</xref>). Both S1 and S2 subunits of S protein-induced chemokines including <italic>CXCL1, CXCL2</italic>, and <italic>CCL2</italic> in THP1 cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Interestingly, three other structural proteins—M, N and E—did not induce any cytokines and chemokines (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). S1 and S2 exerted a synergistic effect on cytokine production when cells were incubated with them together (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). However, other structural proteins, including M, N, and E, had no effect on S-induced inflammatory responses (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Interferons are critical for adaptive immune response and antiviral immunity (<xref ref-type="bibr" rid="bib34">Park and Iwasaki, 2020</xref>). However, THP1 cells did not express either type-I (<italic>IFNA</italic> and <italic>IFNB</italic>) and type-II (<italic>IFNG</italic>) interferons in response to any of the SARS-CoV-2 structural proteins (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Notably, THP1 cells are not defective in producing interferons when activated by PolyI:C, a ligand for TLR3 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>SARS-CoV-2 S protein induces cytokines and chemokines in macrophages and monocytes.</title><p>(<bold>A</bold>) Human monocytic cells THP1-derived macrophages were stimulated with recombinant S1, S2, M, N, and E proteins of SARS-CoV-2 at a concentration of 500 ng/ml. Four hours post-stimulation, the expression of <italic>IL6, IL1B, TNFA, CXCL1, CXCL2, CCL2, IFNA, IFNB,</italic> and <italic>IFNG</italic> was measured by real-time RT-PCR. (<bold>B</bold>) THP1 cells were stimulated with S2 protein at various concentrations for 4 hr and measured the indicated cytokines by real-time RT-PCR. (<bold>C</bold>) THP1 cells were stimulated with S2 protein (500 ng/ml). RNA isolated at 2, 4, and 8 hr post-stimulation was measured for <italic>IL6, IL1B, TNFA, CXCL1,</italic> and <italic>CXCL2</italic> by real-time RT-PCR. (<bold>D</bold>) Human peripheral blood mononuclear cells (PBMCs) were incubated with S2 (500 ng/ml) protein for 4 hr. The expression of <italic>IL6, IL1B, TNFA, CXCL1,</italic> and <italic>CXCL2</italic> was measured by real-time RT-PCR. (<bold>E</bold>) THP1 cells were incubated with S1 (500 ng/ml) or S2 (500 ng/ml) in the presence or absence of ACE2 inhibitor MLN-4760 (10 mM). The expression of cytokines was measured at 4 hr by real-time RT-PCR. Data represent mean ± SD (n=3); *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments described in (<bold>A</bold>) were repeated three times, and (<bold>B–E</bold>) were repeated two times. Data of representative experiments are presented.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Raw source data for A-E.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>SARS-CoV-2 S protein induces inflammatory cytokines in macrophages.</title><p>(<bold>A</bold>) THP1 cells were stimulated with S2 protein. Four hours post-stimulation, culture supernatants were analyzed for IL-6, IL-1β, and TNFα by ELISA. (<bold>B</bold>) THP1 cells were stimulated with S1 and S2 individually or together or in combination with M, N, and E proteins (500 ng/ml each protein). RNA isolated at 4 hr post-stimulation was measured for <italic>IL6, IL1B, and TNFA</italic>. (<bold>C</bold>) THP-1 cells were stimulated with PolyI:C (1 μg/ml). The expression of interferons was measured by real-time RT-PCR. (<bold>D</bold>) THP1 cells were stimulated with native S2 or heat-denatured (HD) S2 (500 ng/ml). The induction of <italic>IL6</italic>, <italic>IL1B</italic>, and <italic>TNFA</italic> was measured by real-time RT-PCR at 4 hr post-stimulation. (<bold>E</bold>) THP1 cells were stimulated with S1, S2, or S-tri manufactured by R&amp;D for 4 hr. The induction of inflammatory cytokines was measured by real-time RT-PCR. Data represent mean ± SD (n=3); **p&lt;0.001, ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Raw source data for A-E.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig1-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Mouse macrophages are stimulated by SARS-CoV-2 S protein.</title><p>(<bold>A</bold>) Bone marrow-derived macrophages from WT mice were stimulated with S1 and S2 proteins (500 ng/ml) for 4 hr. The expression of <italic>Il6</italic>, <italic>Il1b</italic>, <italic>Tnfa</italic>, <italic>Cxcl1</italic>, <italic>Cxcl2, Ifna, Ifnb,</italic> and <italic>Ifng</italic> was measured by real-time RT-PCR. (<bold>B</bold>) RAW264.7 murine macrophage cells were stimulated with S1 or S2 (500 ng/ml) for 4 hr. The expression of <italic>Il6, Il1b</italic>, and <italic>Tnfa</italic> was measured by real-time RT-PCR. Data represent mean ± SD (n=3); *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Raw source data for A-B.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig1-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig1-figsupp2-v3.tif"/></fig></fig-group><p>The expression of cytokines and chemokines in response to S protein was dose dependent (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Similarly, S protein-induced inflammatory response was time dependent, with highest being at 8 hr post stimulation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Notably, heat-denatured S2 protein failed to stimulate THP-1 cells, confirming the specificity of S protein and the requirement of its native structural configuration in inducing inflammatory response (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). S1 and S2 proteins from a different source (R&amp;D) were equally potent in inducing proinflammatory cytokines and chemokines (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). Notably, trimeric S protein (S-tri) is also immunostimulatory, producing cytokines <italic>IL6</italic> and <italic>IL1B</italic>, and chemokines <italic>CXCL1</italic> and <italic>CXCL2</italic> in THP1 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). To obtain direct evidence that S protein can induce inflammatory mediators in human immune cells, we stimulated human peripheral blood mononuclear cells (PBMCs) with S2. There was robust induction of <italic>IL1B, IL6</italic>, <italic>TNFA</italic>, <italic>CXCL1</italic>, and <italic>CXCL2</italic> in hPBMC at 4 hr post-stimulation (<xref ref-type="fig" rid="fig1">Figure 1D</xref>).</p><p>SARS-CoV-2 does not infect mouse cells since S protein does not bind with mouse ACE2 receptor. To understand whether recognition of S protein by ACE2 is required for induction of inflammatory molecules, we stimulated mouse bone marrow-derived macrophages (mBMDMs) with S1 and S2. Surprisingly, both S1 and S2 proteins triggered expression of <italic>Il6, Il1b, Tnfa, Cxcl1 and Cxcl2</italic> in mBMDMs (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Similar to THP1 cells, mBMDMs did not produce type-I and type-II interferons in response to S protein (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Murine macrophage cell line RAW264.7 cells also responded to S2 protein, producing <italic>Il6</italic>, <italic>Tnfa</italic>, and <italic>Il1b</italic> (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). To further examine the role of ACE2 in S-induced inflammatory response, we stimulated THP1 cells with S1 or S2 in the presence or absence of ACE2 inhibitor (MLN-4760). Interestingly, inhibition of ACE2 did not affect cytokine production in response to S protein (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Taken together, SARS-CoV-2 S protein induces proinflammatory cytokines and chemokines in macrophages and monocytes in an ACE2-independent manner.</p></sec><sec id="s2-2"><title>Epithelial cells produce inflammatory mediators in response to SARS-CoV-2 S protein</title><p>SARS-CoV-2 primarily infects epithelial cells of the lung, kidney, intestine, and vascular endothelial cells (<xref ref-type="bibr" rid="bib17">Hoffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Xiao et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Hamming et al., 2004</xref>; <xref ref-type="bibr" rid="bib43">Varga et al., 2020</xref>). However, it is poorly understood whether SARS-CoV-2-infected epithelial cells produce proinflammatory cytokines and contribute to cytokine storm of COVID-19 patients. To address this concern, we stimulated human lung epithelial cells A549 with S1 or S2 proteins. However, there was no induction of <italic>IL6, IL1B, TNFA, CXCL1,</italic> and <italic>CXCL2</italic> in A549 cells in response to S proteins at 4 hr post-stimulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Given that epithelial cells are weaker than innate immune cells in expressing inflammatory mediators, we wondered whether the expression of inflammatory molecules in epithelial cells is delayed. We, therefore, measured cytokines and chemokines in A549 cells following stimulation with S1 and S2 at 12 and 24 hr. Interestingly, both S1 and S2 proteins induced proinflammatory cytokines <italic>IL6</italic>, <italic>IL1B</italic>, <italic>TNFA</italic>, and chemokines <italic>CXCL1</italic> and <italic>CXCL2</italic> with highest being at 24 hr post-stimulation (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similarly, Calu3 cells, a commonly used human lung epithelial cell line, and mouse primary lung epithelial cells produced <italic>IL6</italic>, <italic>IL1B</italic>, <italic>TNFA</italic>, <italic>CXCL1</italic>, and <italic>CXCL2</italic> in response to S protein (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). We confirmed the expression of IL-1β, IL-6, and TNFα at protein levels in Calu3 and primary lung epithelial cells by ELISA (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Lung epithelial cells produce inflammatory molecules in response to SARS-CoV-2 S protein.</title><p>(<bold>A, B</bold>) A549 or Calu3 cells were incubated with SARS-CoV-2 S1 or S2 proteins (500 ng/ml) for 12 and 24 hr. The expression of inflammatory cytokines and chemokines was measured by real-time RT-PCR. (<bold>C</bold>) Primary mouse lung epithelial cells were stimulated with S2 (500 ng/ml) for 12 and 24 hr. The expression of inflammatory cytokines and chemokines was measured by real-time RT-PCR. (<bold>D, E</bold>) Calu3 cells or mouse lung primary epithelial cells were stimulated with S2 (500 ng/ml). Culture supernatant collected at 12 and 24 hr were analyzed for IL-6, IL-1β, and TNFα by ELISA. *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments in (<bold>A, B</bold>) were repeated three times. Other experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw source data for A-E.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Epithelial cells do not respond to SARS-CoV-2 S protein acutely.</title><p>A549 cells were incubated with SARS-CoV-2 S1 or S2 (500 ng/ml) proteins for 4 hr. The expression of inflammatory cytokines and chemokines was measured by real-time RT-PCR. Data represent mean ± SD (n=3). Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig2-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig2-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Epithelial cells expressing S protein trigger inflammation in macrophages</title><p>We next verified whether cytosolic S protein can stimulate epithelial cells to produce inflammatory molecules. Therefore, we transfected A549, Calu3, and HEK293T cells with plasmids expressing S protein or green fluorescent protein (GFP). The expression of S protein in HEK293T, A549, and Calu3 cells was confirmed by Western blotting (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). However, cytosolic S protein did not induce any cytokines and chemokines in A549, Calu3, and HEK293T cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B-D</xref>). These data suggest that cytosolic S protein does not trigger inflammation in epithelial cells.</p><p>Since airway and other epithelial cells are primary targets for SARS-CoV-2, we wondered whether virally infected epithelial cells trigger inflammatory response in macrophages and monocytes in a paracrine manner. To address this concern, we collected culture supernatant of A549-S, Calu3-S, or HEK293T-S cells and added (30% V/V) into THP1 cells in culture (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). However, culture supernatants of epithelial cells expressing S protein failed to induce cytokines <italic>IL6</italic>, <italic>IL1B</italic>, and <italic>TNFA</italic> in THP1 cells (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>, and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>). In fact, S protein was not detectable in the culture supernatant of HEK293T and A549 cells expressing S protein (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). Flow cytometric analysis suggested that S protein is primarily located in the cytoplasm, not on the cell surface (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Epithelial cells expressing S protein stimulate macrophages during co-culture.</title><p>(<bold>A–C</bold>) SARS-CoV-2 S protein was overexpressed in A549 or Calu3 cells. Forty-eight hours following transfection with S or GFP plasmids, cell culture supernatants were collected and added into THP1 cells in culture at 30% v/v. (<bold>B, C</bold>) The expression of <italic>IL6, IL1B</italic>, and <italic>TNFA</italic> in THP1 cells at 4 hr was measured by real-time RT-PCR. (<bold>D</bold>) A549 or Calu3 cells expressing S protein were co-cultured with THP1 cells at 1:2 ratio for 16 hr. (<bold>E, F</bold>) The expression of <italic>IL6, IL1B</italic>, and <italic>TNFA</italic> was measured by real-time RT-PCR. (<bold>G, H</bold>) Protein levels of IL-6<italic>,</italic> IL-1β<italic>,</italic> and TNFα in culture supernatant described in (<bold>D</bold>) were measured by ELISA. Data represent mean ± SD (n=3); **p&lt;0.001, ***p&lt;0.0001 by unpaired Student’s t-test. Experiments were repeated three times and data of representative experiments are presented.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw source data for B, C, E, F, G, H.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig3-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cytosolic S protein dose not trigger inflammation in epithelial cells.</title><p>A549, Calu3, and HEK293T cells were transfected with plasmids containing flag-tagged S or green fluorescent protein (GFP). (<bold>A</bold>) Forty-eight hours post-transfection, cell lysates were collected and the expression of S was measured by Western blot analysis of S protein. (<bold>B–D</bold>) Forty-eight hours following transfection with expression plasmids, the mRNA levels of <italic>IL6, IL1B, TNFA, CXCL1,</italic> and <italic>CXCL2</italic> were measured by real-time RT-PCR. Data represent mean ± SD (n=3). Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Raw source data for B-D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig3-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig3-figsupp1-v3.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>HEK293T cells expressing S protein activate macrophages.</title><p>(<bold>A–B</bold>) Spike or GFP (control) were overexpressed in HEK293T cells. THP1 cells were stimulated with cell culture supernatant (30% v/v) of HEK293T-S or HEK293T-GFP for 4 hr. The expression of <italic>IL6, IL1B</italic>, and <italic>TNFA</italic> was measured by real-time RT-PCR. (<bold>B</bold>) Spike or GFP (control) proteins were overexpressed in HEK293T or A549 cells. Cell culture supernatants and cell lysates were collected at 48 hr after transfection, and analyzed for S protein by ELISA. (<bold>C</bold>) The expression of S on the cell surface of HEK293T-S cells was measured by flow cytometry following surface staining of S protein. (<bold>D, E</bold>) HEK293T cells expressing S protein were co-cultured with THP1 cells at 1:2 ratio for 16 hr. The expression of <italic>IL6, IL1B</italic>, and <italic>TNFA</italic> was measured by real-time RT-PCR (<bold>D</bold>) and ELISA (<bold>E</bold>). (<bold>F</bold>) S or GFP (control) proteins were overexpressed in HEK293T cells. Cells were sonicated, and cell lysate supernatants were collected. THP1 cells were incubated with these cell lysate supernatants for 4 hr. (<bold>G</bold>) The expression of <italic>IL6, IL1B, TNFA, CXCL1,</italic> and <italic>CXCL2</italic> in THP1 cells was measured by real-time RT-PCR. Data represent mean ± SD (n=3); *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Raw source data for A, B, D, E, G.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig3-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig3-figsupp2-v3.tif"/></fig></fig-group><p>We then sought to examine whether innate immune cells become activated when they physically interact with S protein-expressed epithelial cells. Hence, we co-cultured S protein expressing A549, Calu3, or HEK293T cells with THP1 cells at 1:2 ratio (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Interestingly, inflammatory cytokines were induced in co-cultured cells (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, and <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2D</xref>). We confirmed protein concentrations of IL-6, IL-1β, and TNFα in the culture supernatants of co-cultured cells by ELISA (<xref ref-type="fig" rid="fig3">Figure 3G and H</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E</xref>). Notably, similar to <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>, S protein was not detected in the culture supernatant of co-cultured cells as measured by ELISA (data not shown), suggesting that THP1 cells are activated by S protein-transfected epithelial cells through an unknown mechanism.</p><p>To further confirm that cytosolic S protein expressed in epithelial cells can stimulate macrophages, we lysed HEK293T-S cells, and added the cell lysates into THP1 cells in culture (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2F</xref>). Lysates of HEK293T-S cells efficiently induced inflammatory cytokines in THP1 cells while no such induction was observed in response to cell lysate of HEK293T-GFP cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2G</xref>). Taken together, these data imply that SARS-CoV-2 infected epithelial cells may stimulate macrophages and monocytes in a paracrine manner to produce inflammatory mediators.</p></sec><sec id="s2-4"><title>S protein activates the NF-κB pathway</title><p>Inflammatory genes are transcriptionally regulated by transcription factors that are activated by signaling pathways such as NF-κB, MAPK, STAT3, and AKT. To obtain further insight into how S protein induces the expression of inflammatory mediators, we stimulated THP1 cells with S2 protein. Cell lysates collected at various times following stimulation were analyzed for the activation of these inflammatory pathways by Western blotting. As shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, P65 and IκB were phosphorylated in cells treated with S2. MAPK pathways, including ERK, P38, and JNK, are often activated concomitant to the NF-κB pathway. Surprisingly, there was no activation of ERK and JNK in S2 stimulated cells (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). There was also no activation of the AKT pathway (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), but STAT3 was phosphorylated at 2 hr following stimulation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Inflammatory cytokines, such as IL-6, can activate STAT3; thus, the observed activation of STAT3 could be a secondary response of S protein-mediated activation of the NF-κB pathway. S2 protein also activated the NF-κB and STAT3 pathways in A549 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). To confirm that S protein-induced inflammation was NF-κB dependent, we inhibited the NF-κB pathway using Sc514, an inhibitor of IKKβ, during stimulation with S protein. As expected, inhibition of the NF-κB pathway abrogated inflammatory responses in S protein-stimulated macrophages (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>SARS-CoV-2 S protein activates the NF-κB pathway.</title><p>(<bold>A, B</bold>) THP1 and A549 cells were stimulated with S2 (500 ng/ml) for indicated time points. Phosphorylation of P65, IκBα, ERK, JNK, STAT3, and AKT was measured by Western blotting. (<bold>C, D</bold>) THP1 cells were stimulated by SARS-CoV-2 S2 protein (500 ng/ml) in the presence or absence of IKKβ inhibitor sc514. Phosphorylation of P65 and IκBα was measured by Western blotting (<bold>C</bold>). The expression of <italic>IL6, IL1B, TNFA, CXCL1</italic>, and <italic>CXCL2</italic> in stimulated THP1 cells was measured by real-time RT-PCR (<bold>D</bold>). Data represent mean ± SD (n=3); *p&lt;0.05, **p&lt;0.001, ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments in (<bold>A, B</bold>) were repeated three times and (<bold>C, D</bold>) were repeated two times. Data of representative experiments are presented.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw source data for D.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig4-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig4-v3.tif"/></fig></sec><sec id="s2-5"><title>S protein-mediated activation of the NF-κB pathway is TLR2 dependent</title><p>Upon recognition of diverse PAMPs at the cell surface or in the endosome, TLRs activate the NF-κB and MAPK pathways through the adapter protein MyD88. To verify if TLR pathways are involved in S protein-mediated activation of the NF-κB pathway, we stimulated WT and <italic>Myd88<sup>−/</sup></italic><sup>−</sup> BMDM with S2. Interestingly, there was no activation of the NF-κB pathway in <italic>Myd88<sup>−/</sup></italic><sup>−</sup> BMDM (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Consistently, there was no cytokine expression in <italic>Myd88<sup>−/</sup></italic><sup>−</sup> macrophages upon stimulation with S2 protein (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This observation suggests that S protein-mediated activation of the transcription factor NF-κB involves TLR/MyD88 signaling axis. We then interrogated which TLR senses S protein. Since S is a glycoprotein, we anticipated that TLR2, a receptor for lipoprotein, or TLR4, which senses lipopolysaccharide and several other stimuli (<xref ref-type="bibr" rid="bib23">Kawai and Akira, 2006</xref>), could be the immune sensor for S protein. Therefore, we stimulated <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> and <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> BMDMs with S2 protein and measured the activation of the NF-κB pathway. There was no activation of the NF-κB pathway in <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> BMDM, while activation of this pathway was intact in <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> macrophages (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). We confirmed that <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> macrophages were defective in sensing Pam3CSK4, a ligand for TLR2, while they were fully responsive to TLR4 ligand LPS (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Similar to S2, S1 protein activated the NF-κB pathway in WT macrophages but not <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> macrophages (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Consistent to the defective activation of the NF-κB pathway, there was no induction of proinflammatory cytokines in S-stimulated <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> macrophages (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Notably, similar to S protein, S-tri is also sensed by TLR2, but not TLR4, as <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> macrophages failed to induce cytokines in response to S-tri, while no such defect in inflammatory response was observed in <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> macrophages (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Further, inhibition of TLR2 by C29 blocked S2-mediated induction of proinflammatory cytokines in THP1 cells (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). C29 also inhibited S-mediated induction of cytokines and chemokines in Calu3 cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TLR2 recognizes SARS-CoV-2 S protein and activate the NF-κB pathway.</title><p>(<bold>A, B</bold>) Bone marrow-derived macrophages (BMDMs) from WT and <italic>Myd88<sup>−/</sup></italic><sup>−</sup> mice were stimulated with S2 protein (500 ng/ml). (<bold>A</bold>) The activation of the NF-κB pathway was measured by Western blot analysis of P-P65 and P-IκBα. (<bold>B</bold>) The induction of <italic>Il6</italic>, <italic>Il1b,</italic> and <italic>Tnfa</italic> was measured by real-time RT-PCR. (<bold>C</bold>) BMDMs from WT, <italic>Tlr2<sup>−/</sup></italic><sup>−</sup>, and <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> mice were treated with S2 protein (500 ng/ml). Cell lysates collected at different times were analyzed for the activation of the NF-κB pathway by Western blotting of P-P65 and P-IκBα. (<bold>D</bold>) BMDMs from WT and <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice were treated with S1 protein (500 ng/ml), and the activation of P65 and IκBα was measured by Western blotting. (<bold>E, F</bold>) WT, <italic>Tlr2<sup>−/</sup></italic><sup>−</sup>, and <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> macrophages were treated with S2 protein (500 ng/ml) or S-tri (500 ng/ml). The expression of cytokines was measured by real-time RT-PCR at 4 hr post-stimulation. Data represent mean ± SD (n=3); ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented. (<bold>G</bold>) THP1 cells were stimulated with S2 protein (500 ng/ml), Pam3CSK4 (500 ng/ml), or LPS (100 ng/ml) in the presence or absence of Tlr2 inhibitor C29 (150 mM) for 4 hr. The expression of <italic>IL6, IL1B</italic>, and <italic>TNFA</italic> was measured by real-time RT-PCR. (<bold>H</bold>) WT and <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice were administered with S1 and S2 protein (1 μg each/mouse). Blood collected before and 16 hr post S protein administration was measured for IL-6, IL-1β, and TNFα by ELISA. Data represent mean ± SEM (n=5); ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw source data for B, E, F, G, H.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig5-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Macrophages of <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice are defective in sensing TLR2 ligand Pam3CSK4.</title><p>BMDMs from WT and <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice were stimulated with LPS (1 μg/l) or Pam3CSK4 (1 μg/ml) for 4 hr. The expression of inflammatory cytokines was measured by real-time RT-PCR. Data represent mean ± SD (n=3).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Raw source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig5-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Inhibition of TLR2 abrogates S-mediated inflammatory response in Calu-3 cells.</title><p>Calu3 cells were stimulated with S2 (500 ng/ml) in the presence or absence of TLR2-inhibitor C29 (150 mM) for 24 hr. The expression of inflammatory cytokines was measured by real-time RT-PCR. Data represent mean ± SD (n=3); ***p&lt;0.0001 by unpaired Student’s t-test. Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Raw source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig5-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig5-figsupp2-v3.tif"/></fig></fig-group><p>Finally, to understand whether S protein induces inflammation in vivo and the role of TLR2 in this process, we administered S1 and S2 proteins into WT or <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice intraperitoneally (i.p.). 16 hr following administration of S protein, we measured the cytokine IL-6, IL-1β, and TNFα in the serum by ELISA. The concentrations of IL-6, IL-1β, and TNFα were elevated following administration of S proteins in WT mice, whereas no such induction was observed in <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). These data suggest that TLR2 is an innate immune sensor for SARS-CoV-2 S protein, and recognition of S protein by TLR2 leads to the activation of NF-κB and induction of inflammatory mediators.</p></sec><sec id="s2-6"><title>TLR2 requires heterodimerization with TLR1 or TLR6 for sensing S protein</title><p>It is known that TLR2 forms a heterodimer with either TLR1 or TLR6 on the cell surface that promotes ligand binding and propagation of signaling to the downstream kinases (<xref ref-type="bibr" rid="bib3">Buwitt-Beckmann et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Chang et al., 2007</xref>; <xref ref-type="bibr" rid="bib10">Farhat et al., 2008</xref>; <xref ref-type="bibr" rid="bib21">Jin et al., 2007</xref>). We, therefore, asked whether TLR1 or TLR6 is involved in sensing S-mediated inflammatory response. To this end, we used engineered HEK293T cells which selectively express TLR2 (HEK-Blue-TLR2), TLR2 and TLR1 (HEK-Blue-TLR2/1), or TLR2 and TLR6 (HEK-Blue-TLR2/6) along with SEAP (secreted embryonic alkaline phosphatase), a reporter for NF-κB activation. When we stimulated reporter HEK-Blue cells with S1, S2, or S-tri, all three spike proteins activated NF-κB in HEK-Blue-TLR2, HEK-Blue-TLR1/2, and HEK-Blue-TLR2/6 cells, but not in HEK-Blue-Null and HEK-Blue-TLR4 cells (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). We used Pam3CSK4, FSL1, and LPS as control ligands for HEK-Blue-TLR2/1, HEK-Blue-TLR2/6, and HEK-Blue-TLR4 cells, respectively (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Notably, HEK293T cells endogenously express TLR1 and TLR6 (<xref ref-type="bibr" rid="bib3">Buwitt-Beckmann et al., 2006</xref>) therefore, HEK-Blue-TLR2 cells responded to both TLR2/1 ligand Pam3CSK4 and TRL2/6 ligand FSL1 (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). We further examined S-induced activation of NF-κB in TLR2, TLR1/2, and TLR2/6 cells by Western blotting. As shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>, NF-κB was activated in S2 stimulated HEK-Blue-TLR2, HEK-Blue-TLR1/2, and HEK-Blue-TLR2/6 cells but not in HEK-Blue-Null and HEK-Blue-TLR4 cells. Consistently, the S-induced expression of <italic>IL6</italic> and <italic>IL1B</italic> was similar in HEK-Blue-TLR2, HEK-Blue-TLR2/1, and HEK-Blue-TLR2/6 cells (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TLR1 and TLR6 are dispensable in S-mediated activation of TLR2/NF-κB pathway.</title><p>(<bold>A, B</bold>) HEK-Blue-Null, HEK-Blue-TLR2, HEK-Blue-TLR1/2, HEK-Blue-TLR2/6, and HEK-Blue-TLR4 were stimulated with S1, S2, or S-tri for 6 hr. FSL1, Pam3CSK4, and LPS were used as ligands for TLR2/1, TLR2/6, and TLR4, respectively. The activation of NF-κB was monitored by the blue color development (<bold>A</bold>), which was measured at 620 nm (<bold>B</bold>). (<bold>C</bold>) HEK-Blue-Null, HEK-Blue-TLR2, HEK-Blue-TLR1/2, HEK-Blue-TLR2/6, and HEK-Blue-TLR4 cells were stimulated with S2 (500 ng/ml) at indicated times. The activation of P-P65 and P-IκBα was measured by Western blot analysis. (<bold>D</bold>) HEK-Blue-Null, HEK2-Blue-TLR2, HEK-Blue-TLR1/2, HEK-Blue-TLR2/6, and HEK-Blue-TLR4 cells were stimulated with S2 (500 ng/ml) for 6 hr. The induction of <italic>IL6</italic> and <italic>IL1B</italic> was measured by real-time RT-PCR. (<bold>E, F</bold>) HEK-Blue-TLR2, HEK-Blue-TLR2/1, and HEK-Blue-TLR2/6 cells were stimulated with S1 or S2 in the presence or absence of TLR2 inhibitor C29 (150 mM) for 6 hr. The NF-κB activity was monitored colorimetrically at 620 nm. (<bold>G, H</bold>) TLR1, TLR2, TLR6, or TLR1/6 were knocked out in Raw264.7 cells with CRISPR/Cas9. Cells were then stimulated with S2 protein (500 ng/ml) for 4 hr. (<bold>G</bold>) The expression of cytokines was measured by real-time RT-PCR. Data represent mean ± SD (n=5); ***p&lt;0.0001, ****p&lt;0.00001 by unpaired Student’s t-test. All experiments were repeated three times and data of representative experiments are presented.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw source data for B, D, F, G.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig6-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>M, N, and E proteins do not activate TLR2 pathway.</title><p>HEK-Blue-TLR2 and HEK-Blue-TLR4 cells were stimulated with S1, S2, M, N, or E proteins (500 ng/ml of each protein). Six hours following stimulation, blue substrate activation was measured by optical density taken at 620 nm. Data represent mean ± SD (n=3). Experiments were repeated three times and data of representative experiments are presented.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Raw source data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig6-figsupp1-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig6-figsupp1-v3.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Knocking out of TLRs in Raw264.7 cells with CRISPR/Cas9.</title><p><italic>Tlr1</italic>, <italic>Tlr2</italic>, <italic>Tlr6</italic>, or <italic>Tlr1</italic>/<italic>6</italic> were knocked out in Raw264.7 cells with CRISPR/Cas9. (<bold>A</bold>) The expression of <italic>Tlr1</italic>, <italic>Tlr2</italic>, <italic>Tlr6</italic>, and <italic>Tlr4</italic> was measured by real-time RT-PCR. (<bold>B</bold>) Knockout cells were stimulated with Pam3CSK4 (500 ng/ml), FSL1 (100 ng/ml), or LPS (100 ng/ml) for 4 hr. The expression of <italic>Il6</italic> was measured by real-time RT-PCR. Data represent mean ± SD (n=3). Experiments were repeated two times and data of representative experiments are presented.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Raw source data for A-B.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-68563-fig6-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-68563-fig6-figsupp2-v3.tif"/></fig></fig-group><p>Since we observed that both HEK-Blue-TLR1/2 and HEK-Blue-TLR2/6 cells responded to S protein, we wanted to clarify whether TLR1 or TLR6 can sense S protein independent of TLR2. To this end, we inhibited TLR2 in HEK-Blue-TLR cells with C29 during stimulation with S protein. C29 completely blocked S-mediated NF-κB activation in HEK-Blue-TLR2, HEK-Blue-TLR1/2, and HEK-Blue-TLR2/6 cells (<xref ref-type="fig" rid="fig6">Figure 6E and F</xref>), further confirming the essential role of TLR2 in S-mediated innate immune response. Notably, no activation of the reporter gene was observed in HEK-Blue-TLR2 or HEK-Blue-TLR4 cells stimulated with M, N, and E proteins (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A, B</xref>), further confirming that S, but not other structural proteins, is primarily responsible for the inflammatory response.</p><p>With the above observation, we interpreted that TLR1 and TLR6 plays a redundant role or these co-receptors are dispensable in S-induced inflammatory response. To examine these possibilities, we knocked out <italic>TLR1</italic>, <italic>TLR2</italic>, <italic>TLR6</italic>, or both <italic>TLR1</italic> and <italic>TLR6</italic> in Raw264.7 cells with CRISPR/Cas9 (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A, B</xref>). On stimulation of null or different TLR knockout cells with S2, TLR1-KO and TLR6-KO cells showed no defect in the S-induced inflammatory responses (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Interestingly, TLR1 and TLR6 double KO cells failed to induce any cytokine during stimulation with S protein (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Taken together, these data suggest that TLR2 requires dimerization with either TLR1 or TLR6 for sensing S protein and inducing subsequent inflammatory responses.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Both SARS-CoV-2 infection and aberrant host immune responses are responsible for COVID-19 pathogenesis (<xref ref-type="bibr" rid="bib42">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Tay et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Blanco-Melo et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Grant et al., 2021</xref>). The initial host immune response against SARS-CoV-2 infection involves innate immune cells, such as macrophages, monocytes, neutrophils, and dendritic cells (<xref ref-type="bibr" rid="bib30">Liao et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Zhou et al., 2020a</xref>). Cytokines, chemokines, and other inflammatory mediators produced by these cells inhibit virus replication, heal the damage, and activate the adaptive immune system. However, uncontrolled release of cytokines, chemokines, and reactive oxygen and nitrogen species often exert pathological consequences such as tissue injury, systemic inflammation, and organ failure (<xref ref-type="bibr" rid="bib42">Vabret et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Tay et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Blanco-Melo et al., 2020</xref>). Non-surviving COVID-19 patients exhibited a massive influx of macrophages and neutrophils, but reduced T cells in their blood (<xref ref-type="bibr" rid="bib30">Liao et al., 2020</xref>), pointing to the association of hyperactivation of innate immune cells with COVID-19 pathogenesis. Indeed, the innate immune response is heightened in the lung of COVID-19 patients (<xref ref-type="bibr" rid="bib53">Zhou et al., 2020a</xref>; <xref ref-type="bibr" rid="bib49">Xiong et al., 2020</xref>). A better understanding of the mechanism through which SARS-CoV-2 stimulates innate immune cells and activates inflammatory signaling pathways is key to finding better treatment regimens for COVID-19. Our finding that SARS-CoV-2 S protein is a potent viral PAMP involved in the induction of inflammatory cytokines and chemokines via TLR2-dependent activation of the NF-κB pathway, therefore, is a valuable addition to the tremendous scientific effort aiming at combating COVID-19.</p><p>Being an RNA virus, SARS-CoV-2 may activate RNA sensors TLR7, RIG-I, and MDA5, which are primarily responsible for production of type I interferons (<xref ref-type="bibr" rid="bib24">Kawasaki and Kawai, 2014</xref>). Interestingly, the type I interferon response is attenuated in COVID-19 patients and SARS-CoV-2 infected cells (<xref ref-type="bibr" rid="bib2">Blanco-Melo et al., 2020</xref>; <xref ref-type="bibr" rid="bib15">Hadjadj et al., 2020</xref>). Transcriptomic analysis of bronchoalveolar lavage fluid and PBMCs of COVID-19 patients also demonstrated higher expression of proinflammatory cytokines and chemokines, but not type I interferons (<xref ref-type="bibr" rid="bib49">Xiong et al., 2020</xref>). Our knowledge of the type I interferon response of SARS-CoV-2 infected macrophages is limited. However, previous studies on SARS-CoV-1, which share 80% similarity with SARS-CoV-2, showed that macrophages and dendritic cells infected by SARS-CoV-1 produce chemokines CXCL10 and CCL2, but not type I interferons (<xref ref-type="bibr" rid="bib6">Cheung et al., 2005</xref>; <xref ref-type="bibr" rid="bib27">Law et al., 2005</xref>). Lack of an interferon response can be explained by the fact that several structural and non-structural proteins including M, N, PLP, ORF3b, ORF6, and NSP1 inhibit type I interferon signaling (<xref ref-type="bibr" rid="bib39">Siu et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Frieman et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Narayanan et al., 2008</xref>; <xref ref-type="bibr" rid="bib8">Devaraj et al., 2007</xref>; <xref ref-type="bibr" rid="bib11">Frieman et al., 2007</xref>; <xref ref-type="bibr" rid="bib26">Kopecky-Bromberg et al., 2007</xref>). Despite this evidence, the precise mechanism of excessive production of inflammatory cytokines along with reduced expression of type I interferons in COVID-19 patients remains elusive. In this regard, our findings that SARS-CoV-2 S protein is a potential trigger for proinflammatory cytokines and chemokines help understand why the inflammatory response in COVID-19 is marked by elevated levels of proinflammatory cytokines and chemokines, but poor type I interferon response. Our findings suggest that S protein of SARS-CoV-1 and SARS-CoV-2 shares similar inflammatory function (<xref ref-type="bibr" rid="bib45">Wang et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Dosch et al., 2009</xref>). Further studies are required to clarify the relative contributions of S protein, viral RNA, and other non-structural proteins in COVID-19-associated cytokine storm.</p><p>Inflammatory responses of COVID-19 patients are mostly contributed by innate immune cells, but they weakly express ACE2 (<xref ref-type="bibr" rid="bib36">Ropa et al., 2021</xref>). There is no strong evidence that SARS-CoV-2 infects and propagates infection in immune cells. Thus, it is intriguing how innate immune cells become activated to produce inflammatory mediators during SARS-CoV-2 infection. We propose three mechanisms involved in hyperinflammatory responses during SARS-CoV-2 infection. First, innate immune cells like macrophages and monocytes recognize S protein of SARS-CoV-2 at the cell surface through TLR2, leading to the activation of the NF-κB pathway. Immune sensing of S protein is independent of ACE2 since mouse macrophages, whose ACE2 receptor does not bind to S protein, express inflammatory cytokines and chemokines in response to S protein. Further, inhibition of ACE2 does not impair S-induced inflammatory response, indicating that immunostimulatory function of S protein is independent of ACE2. Second, innate immune cells get activated by virally infected epithelial cells. Our data suggest that epithelial cells expressing S protein in the cytosol can activate macrophages when they physically interact. Although the underlying mechanism is not clear, macrophages may engulf or recognize cell surface molecules expressed on SARS-CoV-2 infected epithelial cells. In a third mechanism, like myeloid cells, epithelial cells can be activated by S protein extracellularly, leading to the induction of proinflammatory cytokines and chemokines. Although inflammatory responses of epithelial cells are weaker than that of innate immune cells, epithelial cell-derived chemokines recruit neutrophils, monocytes, and lymphocytes in SARS-CoV-2-infected lungs and thereby contribute to immunopathology of COVID-19 patients.</p><p>Our data demonstrate that TLR2 is the innate immune sensor for the S protein. Being a sensor for lipopeptides and lipoproteins, TLR2 plays a critical role in host defense against many bacterial and viral infections (<xref ref-type="bibr" rid="bib33">Oliveira-Nascimento et al., 2012</xref>). Unlike other TLRs, ligand recognition by TLR2 involves dimerization with TLR1 or TLR6 (<xref ref-type="bibr" rid="bib3">Buwitt-Beckmann et al., 2006</xref>; <xref ref-type="bibr" rid="bib21">Jin et al., 2007</xref>). Since an absence of either TLR1 or TLR6 does not impair S-induced inflammatory response, it seems that TLR2/1 and TLR2/6 heterodimers play redundant roles in sensing S protein. However, S protein failed to induce inflammatory response in macrophages defective in either TLR2 or both TLR1 and TLR6, suggesting that TLR2 alone cannot sense S protein, but requires dimerization with either TLR1 or TLR6. Although TLR2/1 and TLR2/6 heterodimers are considered receptors for tri-acylated and di-acylated lipopeptides, respectively, it is not uncommon that both TLR1 and TLR6 co-receptors can sense a particular PAMPs. For example, both TLR2/1 and TLR2/6 heterodimers are involved in the inflammatory response to core and NS3 proteins of hepatitis C virus (<xref ref-type="bibr" rid="bib5">Chang et al., 2007</xref>).</p><p>Like other MyD88-dependent TLR pathways, ligation of TLR2 leads to the activation of transcription factors NF-κB and AP-1 (<xref ref-type="bibr" rid="bib24">Kawasaki and Kawai, 2014</xref>). Interestingly, while there was activation of NF-κB, AP-1 upstream signaling kinases such as ERK and JNK were not seen activated by S proteins. SARS-CoV-1 S protein activates the NF-κB pathway in human monocyte-derived macrophages (<xref ref-type="bibr" rid="bib45">Wang et al., 2007</xref>; <xref ref-type="bibr" rid="bib9">Dosch et al., 2009</xref>). COVID-19 patients also exhibited increased activation of the NF-κB pathway (<xref ref-type="bibr" rid="bib15">Hadjadj et al., 2020</xref>). Interestingly, in contrast to these findings, a separate study reported that SARS-CoV-1 S protein-expressing baculovirus activates AP-1 but not NF-κB in A549 cells (<xref ref-type="bibr" rid="bib4">Chang et al., 2004</xref>). Future studies dissecting the signaling pathway regulated by S protein of SARS-CoV-1 and CoV-2 may reveal further insights into the mechanisms of S protein-induced inflammation.</p><p>Given the importance of understanding the mechanism of hyperinflammatory response during COVID19, other research groups are also focused in exploring SARS-CoV-2 ligands and pathways involved in inflammatory response (<xref ref-type="bibr" rid="bib38">Shirato and Kizaki, 2021</xref>; <xref ref-type="bibr" rid="bib51">Zhao et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Zheng et al., 2021</xref>). The finding of two recent studies showing that S protein triggers inflammatory response is in agreement with our study (<xref ref-type="bibr" rid="bib38">Shirato and Kizaki, 2021</xref>; <xref ref-type="bibr" rid="bib51">Zhao et al., 2021</xref>). But, unlike our data, these studies showed that S protein is sensed by TLR4 instead of TLR2. However, a separate study demonstrated that SARS-CoV-2 induces inflammation via TLR2, but not TLR4, supporting our data (<xref ref-type="bibr" rid="bib52">Zheng et al., 2021</xref>). Interestingly, it was shown that E protein, but not S protein, is immunostimulatory (<xref ref-type="bibr" rid="bib52">Zheng et al., 2021</xref>). While these studies greatly contributed to our understanding of the mechanism of COVID19 pathogenesis, some of these findings are inconsistent and conflicting. It appears that the recombinant S and E proteins used in those studies were generated in <italic>Escherichia coli</italic>. Thus, it is possible those recombinant proteins were contaminated by bacterial PAMPs. We used recombinant proteins produced in mammalian cell HEK293T, ensuring that the proteins are not contaminated by bacterial PAMPs. Using the endotoxin assay, we further confirmed that the recombinant S proteins are endotoxin-free.</p><p>In summary, this study documents a potential mechanism for the inflammatory response induced by SARS-CoV-2. We demonstrate that SARS-CoV-2 S protein is a potent viral PAMP that upon sensing by TLR2 activates the NF-κB pathway, leading to the expression of inflammatory mediators in innate immune and epithelial cells. The effort so far in combating the COVID-19 pandemic is unprecedented, making it possible for the development of a number of vaccines within a year of outbreak. Since S protein is being targeted by most of the vaccine candidates, it is important to consider its inflammatory function in vaccine design. Moreover, it is critically important to investigate whether <italic>TLR2</italic> polymorphisms are associated with COVID19 pathogenesis and the role of TLR2 in antibody production against SARS-CoV-2 vaccines. Considering the fact that new variants of SARS-CoV-2 with mutations in the S protein spread more easily and may confer more severe disease, the effectiveness of current vaccines remain uncertain (<xref ref-type="bibr" rid="bib35">Plante et al., 2021</xref>). Thus, the importance of developing therapeutic drugs for COVID-19 remains high. This study suggests that TLR2 or its downstream signaling adapters could be therapeutically targeted to mitigate hyperinflammatory response in COVID-19 patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>C57BL6/J (WT), <italic>Myd88<sup>−/</sup></italic><sup>−</sup>, <italic>Tlr2<sup>−/</sup></italic><sup>−</sup>, and <italic>Tlr4<sup>−/</sup></italic><sup>−</sup> mice (all C57BL6/J strain), purchased from Jackson Laboratory were used in this study. All mice were bred and maintained in a specific pathogen-free (SPF) facility at the UT Southwestern Medical Center. All studies were approved by the Institutional Animal Care and Use Committee (IACUC) and were conducted in accordance with the IACUC guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All experimental groups were conducted with age and sex-matched male and female mice. No masking was used during data collection and analysis.</p></sec><sec id="s4-2"><title>Cell culture and maintenance</title><p>The human embryonic kidney epithelial cell line HEK293T (ATCC, CRL-3216), and human lung epithelial cell line A549 (ATCC, CCL-185) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; high glucose, Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum (FBS) (Sigma-Aldrich) and 1% (v/v) PenStrep (Sigma-Aldrich) and maintained in a 5% CO<sub>2</sub> incubator at 37°C. THP1 (ATCC, CRL-TIB-202) cells were cultured in Roswell Park Memorial Institute (RPMI)–1640 medium (R8758, Sigma-Aldrich) supplemented with 10% (v/v) FBS (Sigma-Aldrich) and 1% (v/v) PenStrep (Sigma-Aldrich) and maintained in a 5% CO<sub>2</sub> incubator at 37°C. Calu3 cells (ATCC, HTB-55) were cultured in Eagle’s minimum essential medium (302003, ATCC) supplemented with 10% (v/v) FBS (Sigma-Aldrich) and 1% (v/v) PenStrep (Sigma-Aldrich) and maintained in a 5% CO<sub>2</sub> incubator at 37°C. All cell lines were authenticated using STR profiling and confirmed to be free from mycoplasma contamination by testing with a mycoplasma detection kit (Sigma-Aldrich).</p></sec><sec id="s4-3"><title>In vitro studies with THP-1 macrophage-like cells</title><p>Suspended THP-1 cells were cultured in medium containing 100 ng/ml phorbol-12-myristate 13-acetate (PMA; tlrl, Invivogen) to make them adherent macrophage-like cells. Following 24 hr post PMA treatment, THP-1 macrophage-like cells were washed with pre-warmed RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin and allowed to grow in PMA-free culture medium for the next 12 hr. To examine the effect of SARS-CoV-2 structural proteins on inflammatory responses, THP-1 macrophage-like cells were stimulated with SARS-CoV-2 S1 (RayBiotech, 230-30161), SARS-CoV-2 S2 (RayBiotech, 230-30163), SARS-CoV-2 N (RayBiotech, 230-30164), SARS-CoV-2 M (MyBioSource, MBS8574735), and SARS-CoV-2 E (MyBioSource, MBS9141944) for 4 hr. To validate the immune response of S1 and S2 proteins of RayBiotech, we used recombinant S1 (10569-CV-100), S2 (10594-CV-100), and Spike-trimer (10549-CV-100) proteins purchased from R&amp;D Biosystems.</p></sec><sec id="s4-4"><title>Culture of mouse bone marrow-derived macrophage</title><p>Mouse bone marrow cells were collected as described previously (<xref ref-type="bibr" rid="bib41">Udden et al., 2017</xref>). Bone marrow cells were cultured in L929 cell-conditioned IMDM medium supplemented with 10% FBS, 1% nonessential amino acids, and 1% penicillin-streptomycin for 6 days to differentiate into macrophages. BMDMs were seeded in 12-well cell culture plates at a concentration of 1.2×10<sup>6</sup> cells/well and incubated overnight before in vitro studies. BMDMs were stimulated as described above.</p></sec><sec id="s4-5"><title>Culture and maintenance of HEK-Blue cells</title><p>HEK-Blue-Null2 cells (hkb-null2, InvivoGen), HEK-Blue hTLR2 cells (hkb-htlr2, InvivoGen), HEK-Blue-hTLR2-TLR1 cells (hkb-htlr21, InvivoGen), HEK-Blue hTLR2-TLR6 cells (hkb-htlr26, InvivoGen), and HEK-Blue hTLR4 cells (hkb-htlr4, InvivoGen) were cultured and maintained as per the manufacturer’s instruction.</p></sec><sec id="s4-6"><title>Culture of mouse primary lung epithelial cells</title><p>Primary lung epithelial cells were cultured as described earlier (<xref ref-type="bibr" rid="bib22">Kasinski and Slack, 2013</xref>). Briefly, the mouse was sacrificed under aseptic conditions and the lung was perfused with PBS. The lung was dissected out, washed two times with RPMI-1640, and minced with sterile scissors. RPMI-1640 supplemented with collagenase (1 mg/ml) was added to the minced lung and incubated for 1 hr at 37°C in a 5% CO<sub>2</sub> incubator. The lung homogenate was mix properly and kept on ice to settle down large pieces of lung tissue. The top-half of the suspension was transferred and centrifuged at 1000×<italic>g</italic> for 5 min at 4°C. Following removal of supernatant, cell pellets containing lung epithelial cells were resuspend into the RPMI-1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin and cultured on collagen-coated plates at 37°C in a 5% CO<sub>2</sub> incubator.</p></sec><sec id="s4-7"><title>cDNA constructs and transient transfection</title><p>At 50–60% confluency, HEK293T, A549, and Calu3 cells were transfected with GFP-Flag (VB200507-2985cmv) or SARS-CoV-2 S-Flag (VB200507-2984jyv) (1.5 μg/ml) constructs using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s instructions, and confirmed by observing GFP under fluorescence microscope and Western blot analysis of SARS-CoV-2 S and Flag proteins. Forty-eight hours post-transfection, cells were lysed with RIPA lysis buffer containing complete protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche) for the detection of S protein by Western blot or ELISA, or resuspended in TRIzol reagent (Invitrogen) for the isolation of RNA and subsequent measurement of S mRNA by real-time RT-PCR.</p></sec><sec id="s4-8"><title>CRISPR knockout of TLR in mouse macrophage</title><p>Mouse macrophage cells RAW 264.7 (TIB-71, ATCC) were transfected with GFP-Flag or TLR1 CRISPR/Cas9 (sc-423418, Santa Cruz) or TLR2 CRISPR/Cas9 (sc-423981, Santa Cruz), or TLR6 CRISPR/Cas9 (sc-423420, Santa Cruz) constructs (1.5 μg/ml) using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s instructions. Transfection was confirmed by observing GFP under fluorescence microscope, whereas, knockdown of respective TLRs was confirmed by real-time RT-PCR.</p></sec><sec id="s4-9"><title>In-vitro stimulation of epithelial cells</title><p>To examine the effect of SARS-CoV-2 proteins on inflammatory responses in epithelial cells, HEK293T, A549, and Calu3 cells were stimulated with SARS-CoV-2 S1 (RayBiotech, 230-30161), SARS-CoV-2 S2 (Ray Biotech, 230-30163) for 4, 12 or 24 hr. RNA was isolated and measured for the expression of inflammatory genes by real-time PCR.</p></sec><sec id="s4-10"><title>Co-culture of macrophages and epithelial cells</title><p>HEK293T-GFP and HEK293T-S or A549-GFP and A549-S or Calu3-FGP and Calu3-S cells were cultured with THP1 macrophage-like cells in a ratio of 1:2 (macrophages were twice in number to epithelial cells). Following 16 hr of co-culture, culture medium was collected, filtered with 0.2 μM filter, and used for ELISA. RNA was isolated and measured for the expression of inflammatory genes by real-time RT-PCR.</p></sec><sec id="s4-11"><title>Stimulation of macrophages with conditioned medium of S protein expressed epithelial cells</title><p>At 50–60% confluency, HEK293T, A549, and Calu3 cells were transfected with GFP-Flag or SARS-CoV-2 S-Flag (1.5 μg/ml) constructs using Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s instructions, and confirmed by observing GFP under fluorescence microscope and Western blot analysis of SARS-CoV-2 S and Flag. Forty-eight hours post-transfection, culture medium (conditioned medium) was collected, filtered with 0.2 μM filter, and stored at –80°C. At about 85% confluency, culture medium of THP1 cells was replaced with new media containing 30% (v/v) of epithelial cell-conditioned medium. After 4 hr incubation with conditioned medium, the expression of inflammatory cytokines and chemokines were measured.</p></sec><sec id="s4-12"><title>Real-time reverse transcription (RT)-PCR</title><p>Epithelial cells, BMDMs, THP1 cells, and RAW264.7 cells were lysed in TRIzol reagent (Invitrogen). Total RNA was isolated using TRIzol reagent (Invitrogen) following the manufacturer’s instructions. Isolated RNA was reverse transcribed into cDNA using iScript (Bio-Rad). Real-time RT-PCR was performed using iTaq Universal SYBR Green Supermix (Bio-Rad). Individual expression data were normalized to GAPDH as described earlier (<xref ref-type="bibr" rid="bib18">Hu et al., 2015</xref>).</p></sec><sec id="s4-13"><title>In-vitro studies with human peripheral blood mononuclear cells</title><p>Human PBMCs were obtained from STEMCELL TECHNOLOGIES (70025), and were cultured in RPMI-1640 medium (R8758, Sigma-Aldrich) supplemented with 10% (v/v) FBS (Sigma-Aldrich) and 1% (v/v) penicillin-streptomycin (Sigma-Aldrich) and maintained in a 5% CO<sub>2</sub> incubator at 37°C. After 48 hr, hPBMCs were centrifuged and resuspended in fresh medium for 3 hr, and then stimulated with SARS-CoV-2 S (500 ng/mL) for 4 hr.</p></sec><sec id="s4-14"><title>Inflammatory response of SARS-CoV-2 S protein in mice</title><p>WT and <italic>Tlr2<sup>−/</sup></italic><sup>−</sup> mice were intraperitoneally injected with S1 and S2 subunits of SARS-CoV-2 S protein at equal concentration (1 µg each protein/mouse). Blood was collected before S protein administration by cheek puncturing. Sixteen hours following treatment, mice were sacrificed and blood was drawn from the heart. Serum was separated from the blood by centrifugation and used for the measurement of cytokines by ELISA.</p></sec><sec id="s4-15"><title>ELISA</title><p>BMDMs and THP1 cells were lysed in ice-cold RIPA buffer supplemented with complete protease inhibitor and phosphatase inhibitor cocktails (Roche). Protein concentration was measured by the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific-23227). Serum was isolated from mouse blood by centrifugation at 10,000 RPM for 10 min at 4°C. The concentration of IL-6, IL-1β, and TNF-α in cell culture medium and serum was measured using commercially available ELISA kits (R&amp;D Systems). SARS-CoV-2 S protein in cell lysates was detected by SARS-CoV-2 S ELISA Kit and following the manufacturer’s instruction (RayBiotech, ELV-COVID19S2).</p></sec><sec id="s4-16"><title>Western blotting</title><p>THP1 cells, BMDM, HEK293T, A549, and Calu3 cells were lysed in ice-cold RIPA lysis buffer containing complete protease inhibitor and phosphatase inhibitor cocktails (Roche), resolved by SDS-PAGE, and transferred onto a PVDF membrane. The membranes were immunoblotted with antibodies against Phospho-NF-κB p65 (3033, Cell Signaling), Phospho-IκBα (9246, Cell Signaling), IκBα (4812, Cell Signaling), Phospho-ERK (4370, Cell Signaling), ERK (4695, Cell Signaling), Phospho-JNK (4668, Cell Signaling), Phospho-AKT (4060, Cell Signaling), Phospho-STAT3 (9145, Cell Signaling), SARS-CoV-2 S (GTX632604, GeneTex), and β-actin (A2228, Sigma-Aldrich). Immunoreactive protein bands were detected using ECL super signal west femto substrate reagent (Thermo Fisher Scientific).</p></sec><sec id="s4-17"><title>Flow cytometric analysis of SARS-CoV-2 overexpressed HEK293T cells</title><p>HEK293T cells were transfected with SARS-CoV-2 S plasmid. Forty-eight hours following transfection, cells were trypsinized and processed for cell surface staining. Briefly, 0.5×10<sup>6</sup> cells were resuspended in staining buffer (00-4222-26; eBioscience) and centrifuged at 1500 RPM for 3 min at 4°C. Cells were then incubated with Fc block CD16/32 monoclonal antibody (14-0161-82, eBioscience) and stained with primary antibody SARS-CoV-2 (GTX632604, GeneTex) for 30 min on ice. After washing with staining buffer once, cells were stained with secondary antibody DyLight 488 (35552, Thermo Fisher Scientific) on ice for 1 hr. Finally, cells were washed two times with staining buffer and acquired in flow cytometer (CytoFLEX-Beckman Coulter). Flow cytometric data were analyzed by FlowJo software.</p></sec><sec id="s4-18"><title>Heat inactivation of S2 protein</title><p>S2 protein was heated at 95°C for 30 in. Native of heat-denatured S2 proteins (500 ng/ml) were used to stimulate THP1 cells and measurement of cytokines by real-time RT-PCR.</p></sec><sec id="s4-19"><title>In vitro studies with TLR2 and ACE2 inhibitors</title><p>THP1 cells were pretreated with C29 (150 µM), a TLR2 inhibitor, for 1 hr. Control and C29-treated cells were then stimulated with SARS-CoV-2 S2 (500 ng/ml), Pam3CSK4 (500 ng/ml), or LPS (100 ng/ml) in the presence or absence of Tlr2 inhibitor C29 (150 μM) for 4 hr. Similarly, Calu3 cells were pretreated with C29 (150 μM) for 1 hr, and then control and C29-treated Calu3 cells were stimulated with SARS-CoV-2 S2 (500 ng/ml) for 24 hr. For, inhibition of ACE2, THP1 cells were treated with MLN-4760 at 10 μM concentration during stimulation with S protein. The expression of inflammatory cytokines was measured by real-time RT-PCR.</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>Data are represented as mean ± SD or SEM. Data were analyzed by Prism8 (GraphPad Software) and statistical significance was determined by two-tailed unpaired Student’s t-test. p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Investigation, wrote methods and figure legends</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing - original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All studies were approved by the Institutional Animal Care and Use Committee (IACUC) and were conducted in accordance with the IACUC guidelines and the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The IACUC permit number is 2016-101683.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-68563-transrepform1-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>There is no clinical data and large data set in this paper. The raw data for all graphs presented in this paper are included as source data.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors would like to thank the UT Southwestern Animal Resource Center (ARC) for maintenance and care of our mouse colony. The authors thank Dr. Zhijian 'James' Chen for sharing <italic>Myd88<sup>-/-</sup></italic> mice and Dr. Esra Akbay for sharing A549 cells. Hasan Zaki is supported by The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under Award Number R01DK125352, Cancer Prevention and Research Institute of Texas (CPRIT) Individual Investigator Award (RP200284), and American Cancer Society (ACS) Research Scholar Award (RSG-21-021-01-TBE). Rashmin C Savani holds the William Buchanan Chair in Pediatrics and is funded by a Sponsored Research Agreement with Mallinckrodt Pharmaceuticals, Inc for an unrelated project. John W Schoggins is supported by NIH grant AI158254.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Lavender</surname><given-names>H</given-names></name><name><surname>Gnirss</surname><given-names>K</given-names></name><name><surname>Nehlmeier</surname><given-names>I</given-names></name><name><surname>Niemeyer</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Simmons</surname><given-names>G</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Soilleux</surname><given-names>EJ</given-names></name><name><surname>Jahn</surname><given-names>O</given-names></name><name><surname>Steffen</surname><given-names>I</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease</article-title><source>Journal of Virology</source><volume>85</volume><fpage>13363</fpage><lpage>13372</lpage><pub-id pub-id-type="doi">10.1128/JVI.05300-11</pub-id><pub-id pub-id-type="pmid">21994442</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco-Melo</surname><given-names>D</given-names></name><name><surname>Nilsson-Payant</surname><given-names>BE</given-names></name><name><surname>Liu</surname><given-names>W-C</given-names></name><name><surname>Uhl</surname><given-names>S</given-names></name><name><surname>Hoagland</surname><given-names>D</given-names></name><name><surname>Møller</surname><given-names>R</given-names></name><name><surname>Jordan</surname><given-names>TX</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Panis</surname><given-names>M</given-names></name><name><surname>Sachs</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>TT</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Lim</surname><given-names>JK</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><name><surname>tenOever</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title><source>Cell</source><volume>181</volume><fpage>1036</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmid">32416070</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buwitt-Beckmann</surname><given-names>U</given-names></name><name><surname>Heine</surname><given-names>H</given-names></name><name><surname>Wiesmüller</surname><given-names>K-H</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Brock</surname><given-names>R</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Ulmer</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TLR1- and TLR6-independent recognition of bacterial lipopeptides</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>9049</fpage><lpage>9057</lpage><pub-id pub-id-type="doi">10.1074/jbc.M512525200</pub-id><pub-id pub-id-type="pmid">16455646</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>Y-J</given-names></name><name><surname>Liu</surname><given-names>CY-Y</given-names></name><name><surname>Chiang</surname><given-names>B-L</given-names></name><name><surname>Chao</surname><given-names>Y-C</given-names></name><name><surname>Chen</surname><given-names>C-C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions</article-title><source>Journal of Immunology</source><volume>173</volume><fpage>7602</fpage><lpage>7614</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.12.7602</pub-id><pub-id pub-id-type="pmid">15585888</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Dolganiuc</surname><given-names>A</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins</article-title><source>Journal of Leukocyte Biology</source><volume>82</volume><fpage>479</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1189/jlb.0207128</pub-id><pub-id pub-id-type="pmid">17595379</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Poon</surname><given-names>LLM</given-names></name><name><surname>Ng</surname><given-names>IHY</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><name><surname>Sia</surname><given-names>S-F</given-names></name><name><surname>Wu</surname><given-names>MHS</given-names></name><name><surname>Chan</surname><given-names>K-H</given-names></name><name><surname>Yuen</surname><given-names>K-Y</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis</article-title><source>Journal of Virology</source><volume>79</volume><fpage>7819</fpage><lpage>7826</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.12.7819-7826.2005</pub-id><pub-id pub-id-type="pmid">15919935</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title><source>Nature Reviews. Microbiology</source><volume>14</volume><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>SG</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tseng</surname><given-names>M</given-names></name><name><surname>Barretto</surname><given-names>N</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>Tseng</surname><given-names>C-TK</given-names></name><name><surname>Baker</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>32208</fpage><lpage>32221</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704870200</pub-id><pub-id pub-id-type="pmid">17761676</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosch</surname><given-names>SF</given-names></name><name><surname>Mahajan</surname><given-names>SD</given-names></name><name><surname>Collins</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro</article-title><source>Virus Research</source><volume>142</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2009.01.005</pub-id><pub-id pub-id-type="pmid">19185596</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhat</surname><given-names>K</given-names></name><name><surname>Riekenberg</surname><given-names>S</given-names></name><name><surname>Heine</surname><given-names>H</given-names></name><name><surname>Debarry</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Mages</surname><given-names>J</given-names></name><name><surname>Buwitt-Beckmann</surname><given-names>U</given-names></name><name><surname>Röschmann</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Wiesmüller</surname><given-names>K-H</given-names></name><name><surname>Ulmer</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling</article-title><source>Journal of Leukocyte Biology</source><volume>83</volume><fpage>692</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1189/jlb.0807586</pub-id><pub-id pub-id-type="pmid">18056480</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Kopecky-Bromberg</surname><given-names>SA</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane</article-title><source>Journal of Virology</source><volume>81</volume><fpage>9812</fpage><lpage>9824</lpage><pub-id pub-id-type="doi">10.1128/JVI.01012-07</pub-id><pub-id pub-id-type="pmid">17596301</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Ratia</surname><given-names>K</given-names></name><name><surname>Johnston</surname><given-names>RE</given-names></name><name><surname>Mesecar</surname><given-names>AD</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling</article-title><source>Journal of Virology</source><volume>83</volume><fpage>6689</fpage><lpage>6705</lpage><pub-id pub-id-type="doi">10.1128/JVI.02220-08</pub-id><pub-id pub-id-type="pmid">19369340</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>RA</given-names></name><name><surname>Morales-Nebreda</surname><given-names>L</given-names></name><name><surname>Markov</surname><given-names>NS</given-names></name><name><surname>Swaminathan</surname><given-names>S</given-names></name><name><surname>Querrey</surname><given-names>M</given-names></name><name><surname>Guzman</surname><given-names>ER</given-names></name><name><surname>Abbott</surname><given-names>DA</given-names></name><name><surname>Donnelly</surname><given-names>HK</given-names></name><name><surname>Donayre</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>IA</given-names></name><name><surname>Klug</surname><given-names>ZM</given-names></name><name><surname>Borkowski</surname><given-names>N</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Kihshen</surname><given-names>H</given-names></name><name><surname>Politanska</surname><given-names>Y</given-names></name><name><surname>Sichizya</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Lomasney</surname><given-names>JW</given-names></name><name><surname>Argento</surname><given-names>AC</given-names></name><name><surname>Kruser</surname><given-names>JM</given-names></name><name><surname>Malsin</surname><given-names>ES</given-names></name><name><surname>Pickens</surname><given-names>CO</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Walter</surname><given-names>JM</given-names></name><name><surname>Pawlowski</surname><given-names>AE</given-names></name><name><surname>Schneider</surname><given-names>D</given-names></name><name><surname>Nannapaneni</surname><given-names>P</given-names></name><name><surname>Abdala-Valencia</surname><given-names>H</given-names></name><name><surname>Bharat</surname><given-names>A</given-names></name><name><surname>Gottardi</surname><given-names>CJ</given-names></name><name><surname>Budinger</surname><given-names>GRS</given-names></name><name><surname>Misharin</surname><given-names>AV</given-names></name><name><surname>Singer</surname><given-names>BD</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name><name><surname>Investigators</surname><given-names>NSS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia</article-title><source>Nature</source><volume>590</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03148-w</pub-id><pub-id pub-id-type="pmid">33429418</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Zhuang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Pei</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Anderson</surname><given-names>VM</given-names></name><name><surname>Leong</surname><given-names>AS-Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Multiple organ infection and the pathogenesis of SARS</article-title><source>The Journal of Experimental Medicine</source><volume>202</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1084/jem.20050828</pub-id><pub-id pub-id-type="pmid">16043521</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadjadj</surname><given-names>J</given-names></name><name><surname>Yatim</surname><given-names>N</given-names></name><name><surname>Barnabei</surname><given-names>L</given-names></name><name><surname>Corneau</surname><given-names>A</given-names></name><name><surname>Boussier</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>N</given-names></name><name><surname>Péré</surname><given-names>H</given-names></name><name><surname>Charbit</surname><given-names>B</given-names></name><name><surname>Bondet</surname><given-names>V</given-names></name><name><surname>Chenevier-Gobeaux</surname><given-names>C</given-names></name><name><surname>Breillat</surname><given-names>P</given-names></name><name><surname>Carlier</surname><given-names>N</given-names></name><name><surname>Gauzit</surname><given-names>R</given-names></name><name><surname>Morbieu</surname><given-names>C</given-names></name><name><surname>Pène</surname><given-names>F</given-names></name><name><surname>Marin</surname><given-names>N</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Szwebel</surname><given-names>T-A</given-names></name><name><surname>Merkling</surname><given-names>SH</given-names></name><name><surname>Treluyer</surname><given-names>J-M</given-names></name><name><surname>Veyer</surname><given-names>D</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Tharaux</surname><given-names>P-L</given-names></name><name><surname>Rozenberg</surname><given-names>F</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Kernéis</surname><given-names>S</given-names></name><name><surname>Terrier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><volume>369</volume><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmid">32661059</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>MLC</given-names></name><name><surname>Lely</surname><given-names>AT</given-names></name><name><surname>Navis</surname><given-names>GJ</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>The Journal of Pathology</source><volume>203</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1002/path.1570</pub-id><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Krüger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>N-H</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Pöhlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Kwak</surname><given-names>YT</given-names></name><name><surname>Tekippe</surname><given-names>EM</given-names></name><name><surname>Pasare</surname><given-names>C</given-names></name><name><surname>Malter</surname><given-names>JS</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name><name><surname>Zaki</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The DNA Sensor AIM2 Maintains Intestinal Homeostasis via Regulation of Epithelial Antimicrobial Host Defense</article-title><source>Cell Reports</source><volume>13</volume><fpage>1922</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.10.040</pub-id><pub-id pub-id-type="pmid">26655906</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>S</given-names></name><name><surname>Thomsen</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion</article-title><source>Journal of Virology</source><volume>86</volume><fpage>2900</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1128/JVI.05738-11</pub-id><pub-id pub-id-type="pmid">22258243</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>SE</given-names></name><name><surname>Heo</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Paik</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JO</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide</article-title><source>Cell</source><volume>130</volume><fpage>1071</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.09.008</pub-id><pub-id pub-id-type="pmid">17889651</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasinski</surname><given-names>AL</given-names></name><name><surname>Slack</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Generation of Mouse Lung Epithelial Cells</article-title><source>Bio-Protocol</source><volume>3</volume><elocation-id>e837</elocation-id><pub-id pub-id-type="doi">10.21769/bioprotoc.837</pub-id><pub-id pub-id-type="pmid">27239482</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TLR signaling</article-title><source>Cell Death and Differentiation</source><volume>13</volume><fpage>816</fpage><lpage>825</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401850</pub-id><pub-id pub-id-type="pmid">16410796</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Toll-like receptor signaling pathways</article-title><source>Frontiers in Immunology</source><volume>5</volume><elocation-id>461</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id><pub-id pub-id-type="pmid">25309543</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Godfrey</surname><given-names>V</given-names></name><name><surname>Zaki</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cytosolic Nucleic Acid Sensors in Inflammatory and Autoimmune Disorders</article-title><source>International Review of Cell and Molecular Biology</source><volume>344</volume><fpage>215</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/bs.ircmb.2018.10.002</pub-id><pub-id pub-id-type="pmid">30798989</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopecky-Bromberg</surname><given-names>SA</given-names></name><name><surname>Martínez-Sobrido</surname><given-names>L</given-names></name><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Baric</surname><given-names>RA</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists</article-title><source>Journal of Virology</source><volume>81</volume><fpage>548</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1128/JVI.01782-06</pub-id><pub-id pub-id-type="pmid">17108024</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>HKW</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Ng</surname><given-names>HY</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>YO</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells</article-title><source>Blood</source><volume>106</volume><fpage>2366</fpage><lpage>2374</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-10-4166</pub-id><pub-id pub-id-type="pmid">15860669</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Vasilieva</surname><given-names>N</given-names></name><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Berne</surname><given-names>MA</given-names></name><name><surname>Somasundaran</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Greenough</surname><given-names>TC</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The prevalence, risk factors and outcome of cardiac dysfunction in hospitalized patients with COVID-19</article-title><source>Intensive Care Medicine</source><volume>46</volume><fpage>2096</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1007/s00134-020-06205-0</pub-id><pub-id pub-id-type="pmid">32767075</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nature Medicine</source><volume>26</volume><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0901-9</pub-id><pub-id pub-id-type="pmid">32398875</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Tattersall</surname><given-names>RS</given-names></name><name><surname>Manson</surname><given-names>JJ</given-names></name><collab>HLH Across Speciality Collaboration, UK</collab></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title><source>Lancet</source><volume>395</volume><fpage>1033</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id><pub-id pub-id-type="pmid">32192578</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Lokugamage</surname><given-names>K</given-names></name><name><surname>Kamitani</surname><given-names>W</given-names></name><name><surname>Ikegami</surname><given-names>T</given-names></name><name><surname>Tseng</surname><given-names>C-TK</given-names></name><name><surname>Makino</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells</article-title><source>Journal of Virology</source><volume>82</volume><fpage>4471</fpage><lpage>4479</lpage><pub-id pub-id-type="doi">10.1128/JVI.02472-07</pub-id><pub-id pub-id-type="pmid">18305050</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira-Nascimento</surname><given-names>L</given-names></name><name><surname>Massari</surname><given-names>P</given-names></name><name><surname>Wetzler</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Role of TLR2 in Infection and Immunity</article-title><source>Frontiers in Immunology</source><volume>3</volume><elocation-id>79</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2012.00079</pub-id><pub-id pub-id-type="pmid">22566960</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>A</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19</article-title><source>Cell Host &amp; Microbe</source><volume>27</volume><fpage>870</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.008</pub-id><pub-id pub-id-type="pmid">32464097</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plante</surname><given-names>JA</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Lokugamage</surname><given-names>KG</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Muruato</surname><given-names>AE</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Fontes-Garfias</surname><given-names>CR</given-names></name><name><surname>Mirchandani</surname><given-names>D</given-names></name><name><surname>Scharton</surname><given-names>D</given-names></name><name><surname>Bilello</surname><given-names>JP</given-names></name><name><surname>Ku</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>Z</given-names></name><name><surname>Kalveram</surname><given-names>B</given-names></name><name><surname>Freiberg</surname><given-names>AN</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Plante</surname><given-names>KS</given-names></name><name><surname>Weaver</surname><given-names>SC</given-names></name><name><surname>Shi</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spike mutation D614G alters SARS-CoV-2 fitness</article-title><source>Nature</source><volume>592</volume><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2895-3</pub-id><pub-id pub-id-type="pmid">33106671</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ropa</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Capitano</surname><given-names>ML</given-names></name><name><surname>Van’t Hof</surname><given-names>W</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein</article-title><source>Stem Cell Reviews and Reports</source><volume>17</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1007/s12015-020-10056-z</pub-id><pub-id pub-id-type="pmid">33089452</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirato</surname><given-names>K</given-names></name><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Ujike</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of proteases in the release of porcine epidemic diarrhea virus from infected cells</article-title><source>Journal of Virology</source><volume>85</volume><fpage>7872</fpage><lpage>7880</lpage><pub-id pub-id-type="doi">10.1128/JVI.00464-11</pub-id><pub-id pub-id-type="pmid">21613395</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirato</surname><given-names>K</given-names></name><name><surname>Kizaki</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages</article-title><source>Heliyon</source><volume>7</volume><elocation-id>e06187</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06187</pub-id><pub-id pub-id-type="pmid">33644468</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>CP</given-names></name><name><surname>Kok</surname><given-names>KH</given-names></name><name><surname>Chiu-Yat Woo</surname><given-names>P</given-names></name><name><surname>Jin</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain</article-title><source>Cellular &amp; Molecular Immunology</source><volume>11</volume><fpage>141</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1038/cmi.2013.61</pub-id><pub-id pub-id-type="pmid">24509444</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>MZ</given-names></name><name><surname>Poh</surname><given-names>CM</given-names></name><name><surname>Rénia</surname><given-names>L</given-names></name><name><surname>MacAry</surname><given-names>PA</given-names></name><name><surname>Ng</surname><given-names>LFP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0311-8</pub-id><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udden</surname><given-names>SMN</given-names></name><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Gan</surname><given-names>JL</given-names></name><name><surname>Shelton</surname><given-names>JM</given-names></name><name><surname>Malter</surname><given-names>JS</given-names></name><name><surname>Hooper</surname><given-names>LV</given-names></name><name><surname>Zaki</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways</article-title><source>Cell Reports</source><volume>19</volume><fpage>2756</fpage><lpage>2770</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.05.084</pub-id><pub-id pub-id-type="pmid">28658623</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vabret</surname><given-names>N</given-names></name><name><surname>Britton</surname><given-names>GJ</given-names></name><name><surname>Gruber</surname><given-names>C</given-names></name><name><surname>Hegde</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kuksin</surname><given-names>M</given-names></name><name><surname>Levantovsky</surname><given-names>R</given-names></name><name><surname>Malle</surname><given-names>L</given-names></name><name><surname>Moreira</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>MD</given-names></name><name><surname>Pia</surname><given-names>L</given-names></name><name><surname>Risson</surname><given-names>E</given-names></name><name><surname>Saffern</surname><given-names>M</given-names></name><name><surname>Salomé</surname><given-names>B</given-names></name><name><surname>Esai Selvan</surname><given-names>M</given-names></name><name><surname>Spindler</surname><given-names>MP</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>van der Heide</surname><given-names>V</given-names></name><name><surname>Gregory</surname><given-names>JK</given-names></name><name><surname>Alexandropoulos</surname><given-names>K</given-names></name><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>BD</given-names></name><name><surname>Greenbaum</surname><given-names>B</given-names></name><name><surname>Gümüş</surname><given-names>ZH</given-names></name><name><surname>Homann</surname><given-names>D</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Kamphorst</surname><given-names>AO</given-names></name><name><surname>Curotto de Lafaille</surname><given-names>MA</given-names></name><name><surname>Mehandru</surname><given-names>S</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><name><surname>Samstein</surname><given-names>RM</given-names></name><collab>Sinai Immunology Review Project</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Immunology of COVID-19: Current State of the Science</article-title><source>Immunity</source><volume>52</volume><fpage>910</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.002</pub-id><pub-id pub-id-type="pmid">32505227</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varga</surname><given-names>Z</given-names></name><name><surname>Flammer</surname><given-names>AJ</given-names></name><name><surname>Steiger</surname><given-names>P</given-names></name><name><surname>Haberecker</surname><given-names>M</given-names></name><name><surname>Andermatt</surname><given-names>R</given-names></name><name><surname>Zinkernagel</surname><given-names>AS</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name><name><surname>Schuepbach</surname><given-names>RA</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Endothelial cell infection and endotheliitis in COVID-19</article-title><source>Lancet</source><volume>395</volume><fpage>1417</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30937-5</pub-id><pub-id pub-id-type="pmid">32325026</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><volume>181</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>She</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway</article-title><source>Virus Research</source><volume>128</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2007.02.007</pub-id><pub-id pub-id-type="pmid">17532082</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xiang</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title><source>JAMA</source><volume>323</volume><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmid">32031570</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>ZG</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>ZW</given-names></name><name><surname>Tian</surname><given-names>JH</given-names></name><name><surname>Pei</surname><given-names>YY</given-names></name><name><surname>Yuan</surname><given-names>ML</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Dai</surname><given-names>FH</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>QM</given-names></name><name><surname>Zheng</surname><given-names>JJ</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Zhang</surname><given-names>YZ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evidence for Gastrointestinal Infection of SARS-CoV-2</article-title><source>Gastroenterology</source><volume>158</volume><fpage>1831</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.055</pub-id><pub-id pub-id-type="pmid">32142773</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients</article-title><source>Emerging Microbes &amp; Infections</source><volume>9</volume><fpage>761</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1747363</pub-id><pub-id pub-id-type="pmid">32228226</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Tai</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>P</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>FS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>The Lancet. Respiratory Medicine</source><volume>8</volume><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id><pub-id pub-id-type="pmid">32085846</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Kuang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>You</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 spike protein interacts with and activates TLR41</article-title><source>Cell Research</source><volume>31</volume><fpage>818</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1038/s41422-021-00495-9</pub-id><pub-id pub-id-type="pmid">33742149</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Fitzpatrick</surname><given-names>E</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines</article-title><source>Nature Immunology</source><volume>22</volume><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id><pub-id pub-id-type="pmid">33963333</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients</article-title><source>Cell Host &amp; Microbe</source><volume>27</volume><fpage>883</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.017</pub-id><pub-id pub-id-type="pmid">32407669</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>X-L</given-names></name><name><surname>Wang</surname><given-names>X-G</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>H-R</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>C-L</given-names></name><name><surname>Chen</surname><given-names>H-D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>R-D</given-names></name><name><surname>Liu</surname><given-names>M-Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>X-R</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>X-S</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Q-J</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>L-L</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Zhan</surname><given-names>F-X</given-names></name><name><surname>Wang</surname><given-names>Y-Y</given-names></name><name><surname>Xiao</surname><given-names>G-F</given-names></name><name><surname>Shi</surname><given-names>Z-L</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent <break/>(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J</td><td align="left" valign="bottom">Jackson <break/>Laboratory</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:MGI:3028467">MGI:3028467</ext-link><break/>JAX:000664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Myd88<sup>−/</sup></italic><sup>−</sup> C57BL/6J</td><td align="left" valign="bottom">Jackson <break/>Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Tlr2<sup>−/</sup></italic><sup>−</sup> C57BL/6J</td><td align="left" valign="bottom">Jackson <break/>Laboratory</td><td align="left" valign="bottom">B6.129-Tlr2tm<break/>1kir/J<break/>Stock No: <break/>004650</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Tlr4<sup>−/</sup></italic><sup>−</sup> C57BL/6J</td><td align="left" valign="bottom">Jackson <break/>Laboratory</td><td align="left" valign="bottom">B6.B10ScN-<break/>Tlr4lps-del/JthJ<break/>Stock No: 007227</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK-293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-3216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">A549</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-185</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">THP1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-TIB-202</td><td align="left" valign="bottom">Cat# CRL-TIB-202</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Calu-3</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# HTB-55</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-Blue-Null2</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# hkb-null2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-Blue-hTLR2</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# hkb-htlr2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-Blue-hTLR2-TLR1</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# hkb-htlr21</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-Blue hTLR2-TLR6</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# hkb-htlr26</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK-Blue-hTLR4</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# hkb-htlr4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Peripheral <break/>blood <break/>mononuclear <break/>cells</td><td align="left" valign="bottom">StemCell Technologies</td><td align="left" valign="bottom">Cat# 70025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Bone marrow-<break/>derived <break/>macrophage</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Culture of <break/>mouse bone-<break/>marrow-derived <break/>macrophages’ in <break/>Materials and methods</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Primary lung <break/>epithelial <break/>cells</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Culture of <break/>mouse primary <break/>lung epithelial <break/>cells’ in Materials <break/>and methods</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">RAW264.7</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# TIB-71</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit <break/>monoclonal) <break/>Phospho-NF-<break/>kB p65</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 3033</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) <break/>Phospho-IκBα</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9246</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit <break/>monoclonal) <break/>IκBα</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4812</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) <break/>anti-phospho <break/>p44/42 (ERK1/2)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4370</td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) <break/>anti-p44/42 (ERK1/2)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4695</td><td align="left" valign="bottom">WB (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) <break/>anti-phospho SAPK/JNK</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4668</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) <break/>anti-phospho AKT</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 4060</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Rabbit monoclonal) <break/>anti-phospho STAT3</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 9145</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse monoclonal) <break/>anti-SARS-CoV-2 S</td><td align="left" valign="bottom">GeneTex</td><td align="left" valign="bottom">Cat# GTX632604</td><td align="left" valign="bottom">WB (1:1000)<break/>FACS (1 μl/<break/>1×10<sup>6</sup> cells)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Monoclonal) <break/>anti-<break/>CD16/CD32</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 14-0161-82</td><td align="left" valign="bottom">FACS (1 μg/1×10<sup>6</sup> cells)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">(Mouse <break/>monoclonal) <break/>anti-β-actin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# A2228</td><td align="left" valign="bottom">WB (1:10,000)</td></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">GFP-Flag (plasmid)</td><td align="left" valign="bottom">VectorBuilder</td><td align="left" valign="bottom">Cat# VB200507-<break/>2985cmv</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">SARS-CoV-2 S-Flag</td><td align="left" valign="bottom">VectorBuilder</td><td align="left" valign="bottom">Cat# VB200507-<break/>2984jyv</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">TLR1 CRISPR/Cas9</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# sc-423418</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">TLR2 CRISPR/Cas9</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# sc-423981</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant <break/>DNA reagent</td><td align="left" valign="bottom">TLR6 CRISPR/Cas9</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat# sc-423420</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Il1b</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTCGTG<break/>CTGTCGG<break/>ACCCATA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Il1b</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGCAGGGT<break/>GGGTGTG<break/>CCGTCTT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Il6</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAA GAA AGA <break/>CAA AGC <break/>CAG AGT C</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Il6</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAA ATT GGG <break/>GTA GGA <break/>AGG AC</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Tnfa</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCCCAGGTTC<break/>TCTTCAAGGGA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Tnfa</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGTGAGGAG<break/>CACGTAGTCGG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifng</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GAAAGACAA<break/>TCAGGCCATCA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifng</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TTGCTGTTGC<break/>TGAAGAAGGT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifnb</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTGGATG<break/>GTGGTC<break/>CGAGCA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifnb</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TACCAGTCC<break/>CAGAGTCC<break/>GCCTCT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifna</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCTGATGCA<break/>GCAGGTGGG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Ifna</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGGCTCT<break/>CCAGACTTC<break/>TGCTCTG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Cxcl1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TGAGCTGCG<break/>CTGTCA<break/>GTGCCT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Cxcl1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGAAGCCA<break/>GCGTTCA<break/>CCAGA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Cxcl2</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CAA GAA CAT <break/>CCA GAG CTT <break/>GAG TGT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">m_<italic>Cxcl2</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCC CTT GAG <break/>AGT GGC TAT <break/>GAC TT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IL1B</italic> _F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AAATACCTG<break/>TGGCCTTGGGC</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IL1B</italic> _F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TTTGGGATC<break/>TACACTC<break/>TCCAGCT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IL6</italic> _F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTAGCCGC<break/>CCCACACAGA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IL6</italic> _R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CATGTCTCCT<break/>TTCTCAG<break/>GGCTG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>TNFA</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCCAGGGA<break/>CCTCTCT<break/>CTAATCA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>TNFA</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCTTGAGGG<break/>TTTGCTA<break/>CAACATG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IFNG</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCAACGCAAA<break/>GCAATACATGA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IFNG</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCTTTTTCG<break/>CTTCCCT<break/>GTTTTA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IFNB</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ATTGCCTCAA<break/>GGACAGGATG</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IFNB</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GGCCTTCA<break/>GGTAA<break/>TGCAGAA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>IFNA</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GTGAGGAAAT<break/>ACTTCCAAA<break/>GAATCAC</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based <break/>reagent</td><td align="left" valign="bottom">h_<italic>IFNA</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">TCTCATGAT<break/>TTCTGCTCT<break/>GACAA</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CXCL1</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AACCGAAGT<break/>CATAGCCACAC</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CXCL1</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CCTCCCTTC<break/>TGGTCAGTT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CXCL2</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">CGCCCAAAC<break/>CGAAGTCAT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CXCL2</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GATTTGCCATT<break/>TTTCAG<break/>CATCTTT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CCL2</italic>_F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">AGGTGACTGG<break/>GGCATTGAT</td></tr><tr><td align="left" valign="bottom">Sequence-<break/>based reagent</td><td align="left" valign="bottom">h_<italic>CCL2</italic>_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">GCCTCCAGCA<break/>TGAAAGTCTC</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 S1</td><td align="left" valign="bottom">RayBiotech</td><td align="left" valign="bottom">Cat# 230-30161</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 S1</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat# 10569-<break/>CV-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 S2</td><td align="left" valign="bottom">RayBiotech</td><td align="left" valign="bottom">Cat# 230-30163</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 S2</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat# 10594-<break/>CV-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 S-trimer</td><td align="left" valign="bottom">R&amp;D</td><td align="left" valign="bottom">Cat# 10549-<break/>CV-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 N</td><td align="left" valign="bottom">RayBiotech</td><td align="left" valign="bottom">Cat# 230-30164</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 M</td><td align="left" valign="bottom">MyBioSource</td><td align="left" valign="bottom">Cat# MBS8574735</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">SARS-CoV-2 E</td><td align="left" valign="bottom">MyBioSource</td><td align="left" valign="bottom">Cat# MBS9141944</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Pierce BCA <break/>Protein Assay <break/>Kit</td><td align="left" valign="bottom">Thermo Fisher <break/>Scientific</td><td align="left" valign="bottom">Cat# 23227</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Mouse IL-6 ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY406-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Mouse IL-1β ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY401-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Mouse TNF-α ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY410-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Human IL-6 ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY206-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">commercial <break/>assay or kit</td><td align="left" valign="bottom">Human IL-1β ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#<break/>DY201-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">Human TNF-α ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat# DY210-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial <break/>assay or kit</td><td align="left" valign="bottom">SARS-CoV-2 S ELISA Kit</td><td align="left" valign="bottom">RayBiotech</td><td align="left" valign="bottom">Cat# ELV-COVID19S2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Phorbol-12-<break/>myristate 13-<break/>acetate (PMA)</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# tlrl</td><td align="char" char="." valign="bottom">100 ng/ ml</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">TLR2-IN-C29</td><td align="left" valign="bottom">Selleckchem</td><td align="left" valign="bottom">S6597</td><td align="left" valign="bottom">150 μM/ ml</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Pam3CSK4</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">tlrl-pms</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">FSL-1</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">tlrl-fsl</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">ACE2 Inhibitor, <break/>MLN-4760</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">5306160001</td><td align="left" valign="bottom">10 μM/ ml</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Lipofectamine 3000</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# L3000015</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, <break/>drug</td><td align="left" valign="bottom">Ultrapure <break/><italic>Escherichia coli</italic>-<break/>derived LPS</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat# tlrl-smlps</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Flowjo v10</td><td align="left" valign="bottom">Treestar, Inc</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">CytoFLEX-</td><td align="left" valign="bottom">Beckman Coulter</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">Graphpad.com</ext-link></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_00279">SCR_00279</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68563.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>Your paper provides an important advance regarding the role of SARS-CoV-2 spike protein as an inducer of the innate inflammatory cascade in both epithelial cells and macrophages. This is an important early event in development of the cytokine storm associated with COVID-19 and may be of therapeutic relevance.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68563.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Schiffer</surname><given-names>Joshua T</given-names></name><role>Reviewing Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Allen</surname><given-names>Coy</given-names></name><role>Reviewer</role><aff><institution/><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.03.16.435700">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.03.16.435700v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Coy Allen (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The authors should discuss why their finding regarding TLR4 signaling appear to differ from those of other groups.</p><p>2) Repeat experiments with concurrent exposure to S1, S2, M, N, and E proteins would provide a more comprehensive picture of viral infection, and a nice comparison to S1 and S2 alone.</p><p>3) Experiments should be repeated in Calu-3 cells which are permissive to SARS-CoV-2.</p><p>4) The authors should probe the mechanisms of cytokine production in macrophage via TLR2.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>As mentioned above, in general the studies are well done and the data supports the overall conclusions of the manuscript. However, the following comments should be considered in an effort to strengthen the work presented:</p><p>1) TLR2 signals as a heterodimer. Thus, it is not clear if the mechanism proposed is associated with the TLR1/2 or the TLR2/6 heterodimer. This is critical information necessary to confidently define the mechanism proposed.</p><p>2) A549 cells are refractory to SARS-CoV-2 infection (multiple sources, including The Lancet, 2020). Thus, their use here lacks significant physiological relevance. The epithelial cell studies should be conducted or at least confirmed in a more relevant cells line, such as the Calu-3 cells.</p><p>3) The direct connection between the TLR2/MyD88 mechanism in the mouse studies and the human cell line studies is lacking. The team states in the methods that they utilize C29 to attenuate TLR2 function in THP1s. However, the data provided is minimal. These studies should be repeated in all cell lines and include full panels of controls (such as polyI:C and PAM3) and evaluated across a time frame. A stronger study would be adding knockdown data in their cell lines to confirm the mouse studies.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The findings of this study are of potential importance. However, they are preliminary in nature and the biologic relevance of these findings remains unclear. A number of potential approaches could be taken to show biological relevance. Do macrophages infected with the SARS-CoV-2 virus induce cytokine production in a TLR2 dependent manner? Are human TLR2 polymorphisms associated with disease severity or response to vaccination? Is TLR2 required for effective vaccine responses for vaccines based on the spike protein?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.68563.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors should discuss why their finding regarding TLR4 signaling appear to differ from those of other groups.</p></disp-quote><p>Thank you for the suggestion. Two recent publications reported that spike protein is sensed by TLR4 (Shirato K, Heliyon, 2021; Zhao Y, Cell Res, 2021), while another paper showed that SARS-CoV-2 triggers inflammation via TLR2 (Zheng M, Nat Immunol, 2021). We believe that the discrepant results of those studies are possibly due to endotoxin contamination of the recombinant proteins used in those studies as they were generated in <italic>E. coli</italic>. To avoid this problem, we used recombinant proteins generated in mammalian HEK293T cells. We have now included a discussion on this issue in page 16.</p><disp-quote content-type="editor-comment"><p>2) Repeat experiments with concurrent exposure to S1, S2, M, N, and E proteins would provide a more comprehensive picture of viral infection, and a nice comparison to S1 and S2 alone.</p></disp-quote><p>As per recommendation, we have performed additional experiments in which we measured the effect of concurrent exposure of all structural proteins. The new data are now presented as Figure 1—figure supplement 1B. Our data suggest that other structural proteins do not have any positive or negative influence on S-induced inflammatory responses.</p><disp-quote content-type="editor-comment"><p>3) Experiments should be repeated in Calu-3 cells which are permissive to SARS-CoV-2.</p></disp-quote><p>We appreciate the reviewers’ and editor’s suggestion of repeating crucial experiments in Calu3 cells. We have now included a series of studies using Calu3 cells. The new studies are now presented as Figures 2B, 2D, 3C, 3F, 3H, Figure 3—figure supplement 1C and Figure 5—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>4) The authors should probe the mechanisms of cytokine production in macrophage via TLR2.</p></disp-quote><p>We have demonstrated that S protein triggers inflammation via TLR2. Since TLR2 heterodimerizes with TLR1 or TLR6, it is a valid concern whether these coreceptors are involved in S-induced cytokine production. To address the reviewer’s concerns, we have used engineered HEK293T cells expressing TLR2, TLR2/TLR1or TLR2/TLR6 and showed that S protein can be sensed by both TLR2/1 and TLR2/6 heterodimers. Further, we knocked down TLR1, TLR2, TLR6 or TLR1 and TLR6 together in RAW264.7 macrophages. Following stimulation with S protein, we observed that cytokine production was abrogated when TLR2 and TLR1/6 were knocked out. These data suggest that upon ligation with S protein TLR2 in association with either TLR1 or TLR6 activates the downstream NF-κB pathway. Our new findings are shown in Figure 6, Figure 6—figure supplement 1 and Figure 6—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>As mentioned above, in general the studies are well done and the data supports the overall conclusions of the manuscript. However, the following comments should be considered in an effort to strengthen the work presented:</p></disp-quote><p>We greatly appreciate the reviewer’s insightful comments on this manuscript. We found that the reviewer’s comments and concerns were very constructive and helped us improve the quality of our studies. We have performed a series of additional studies to thoroughly address all of the concerns.</p><disp-quote content-type="editor-comment"><p>1) TLR2 signals as a heterodimer. Thus, it is not clear if the mechanism proposed is associated with the TLR1/2 or the TLR2/6 heterodimer. This is critical information necessary to confidently define the mechanism proposed.</p></disp-quote><p>The reviewer has pointed out an important concern. To understand whether heterodimerization with TLR1 and TLR6 is required for TLR2 in sensing S protein, we used HEK293T reporter cells overexpressing TLR2, TLR2/TLR1 or TLR2/TLR6. Interestingly, all three cells were responsive to S1, S2, and S-tri (Figure 6A-D). The inflammatory response of these reporter cells was inhibited when TLR2 was blocked by C29 (Figure 6E and F), suggesting that TLR2 is essential for sensing S protein. Given that HEK293T cells express low level of TLR1 and TLR6, but not TLR2, our data suggest that TLR2 heterodimerizes with either TLR1 or TLR6 in sensing S protein. To further verify this interpretation, we knocked out TLR2, TLR1, TLR6 or both TLR1 and TLR6 in the macrophage cell line. Following stimulation with S protein, we observed that cytokine production was abrogated in TLR2-KO and TLR1/6-double KO cells (Figure 6G, Figure 6—figure supplement 2). These data suggest that upon ligation with S protein TLR2 in association with either TLR1 or TLR6 activates the downstream NF-κB pathway.</p><disp-quote content-type="editor-comment"><p>2) A549 cells are refractory to SARS-CoV-2 infection (multiple sources, including The Lancet, 2020). Thus, their use here lacks significant physiological relevance. The epithelial cell studies should be conducted or at least confirmed in a more relevant cells line, such as the Calu-3 cells.</p></disp-quote><p>We appreciate the reviewer’s valuable suggestion. We have now included a series of studies using Calu3 cells. The new studies are now presented as Figures 2B, 2C, 3F, 3H, and Figure 3—figure supplement 1A and 1C, and Figure 5—figure supplement 2. These experiments demonstrated that, like A549 cells, Calu3 cells are stimulated by S proteins to produce cytokines and chemokines.</p><disp-quote content-type="editor-comment"><p>3) The direct connection between the TLR2/MyD88 mechanism in the mouse studies and the human cell line studies is lacking. The team states in the methods that they utilize C29 to attenuate TLR2 function in THP1s. However, the data provided is minimal. These studies should be repeated in all cell lines and include full panels of controls (such as polyI:C and PAM3) and evaluated across a time frame. A stronger study would be adding knockdown data in their cell lines to confirm the mouse studies.</p></disp-quote><p>We agree with the reviewers that additional controls should be included in studies where TLR2 was blocked by C29. We repeated the study including controls such as LPS and Pam3CSK4. Our data shown in Figure 5G confirms that C29 only inhibits the TLR2 pathway.</p><p>As per reviewer’s recommendation, we also evaluated the effect of C29 in Calu3 cells. Our data showed that C29 inhibits S-mediated cytokine production in Calu3 cells (Figure 5—figure supplement 2).</p><p>Finally, we show that RAW264.7 cells do not respond to S protein when TLR2 was knocked out with CRISPR/Cas9 (Figure 6G). All these data consistently and rigorously support the conclusion that TLR2 is the innate immune receptor for S protein and is involved in inflammatory response.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The findings of this study are of potential importance. However, they are preliminary in nature and the biologic relevance of these findings remains unclear. A number of potential approaches could be taken to show biological relevance. Do macrophages infected with the SARS-CoV-2 virus induce cytokine production in a TLR2 dependent manner? Are human TLR2 polymorphisms associated with disease severity or response to vaccination? Is TLR2 required for effective vaccine responses for vaccines based on the spike protein?</p></disp-quote><p>We greatly appreciate the reviewers’ insightful comments and finding our study potentially important. We completely agree with the reviewer that showing inflammatory response of macrophage to live SARS-CoV2 is TLR2 dependent would make our finding more compelling. Due to the limitation of available resources for working with live SARS-CoV2, we were not able to perform such an experiment. However, a recent study has already addressed this concern showing that macrophages from <italic>Tlr2<sup>-/-</sup></italic> mice are defective in cytokine production when infected with SARS-CoV-2 (Zheng M, Nat Immunol, 2021).</p><p>The reviewer’s comments on the role of TLR2 in vaccine response and an association of TLR2 polymorphism in severity of COVID19 are insightful and important. However, addressing these concerns is out of scope of this study, but we are working on these topics which will be reported in our future studies. We briefly discussed this issue in page 18.</p></body></sub-article></article>